US20130289377A1 - Method and apparatus for cardiac function monitoring - Google Patents
Method and apparatus for cardiac function monitoring Download PDFInfo
- Publication number
- US20130289377A1 US20130289377A1 US13/794,869 US201313794869A US2013289377A1 US 20130289377 A1 US20130289377 A1 US 20130289377A1 US 201313794869 A US201313794869 A US 201313794869A US 2013289377 A1 US2013289377 A1 US 2013289377A1
- Authority
- US
- United States
- Prior art keywords
- hydrophone
- opening
- lead
- along
- lead body
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 35
- 238000012544 monitoring process Methods 0.000 title description 31
- 230000004217 heart function Effects 0.000 title description 13
- 230000000747 cardiac effect Effects 0.000 claims abstract description 49
- 230000004044 response Effects 0.000 claims abstract description 23
- 210000000748 cardiovascular system Anatomy 0.000 claims abstract description 5
- 238000002560 therapeutic procedure Methods 0.000 description 43
- YWTYJOPNNQFBPC-UHFFFAOYSA-N imidacloprid Chemical compound [O-][N+](=O)\N=C1/NCCN1CC1=CC=C(Cl)N=C1 YWTYJOPNNQFBPC-UHFFFAOYSA-N 0.000 description 34
- 230000017531 blood circulation Effects 0.000 description 32
- 210000002216 heart Anatomy 0.000 description 31
- 238000004458 analytical method Methods 0.000 description 24
- 210000004115 mitral valve Anatomy 0.000 description 20
- 210000005241 right ventricle Anatomy 0.000 description 20
- 210000000591 tricuspid valve Anatomy 0.000 description 17
- 206010000891 acute myocardial infarction Diseases 0.000 description 16
- 210000001765 aortic valve Anatomy 0.000 description 16
- 206010019280 Heart failures Diseases 0.000 description 15
- 230000033764 rhythmic process Effects 0.000 description 14
- 210000001367 artery Anatomy 0.000 description 13
- 238000001514 detection method Methods 0.000 description 13
- 230000035945 sensitivity Effects 0.000 description 13
- 230000008859 change Effects 0.000 description 12
- 230000006854 communication Effects 0.000 description 12
- 238000004891 communication Methods 0.000 description 12
- 210000000709 aorta Anatomy 0.000 description 11
- 230000001276 controlling effect Effects 0.000 description 11
- 210000005240 left ventricle Anatomy 0.000 description 11
- 230000002596 correlated effect Effects 0.000 description 10
- 210000003102 pulmonary valve Anatomy 0.000 description 10
- 210000005242 cardiac chamber Anatomy 0.000 description 9
- 238000009125 cardiac resynchronization therapy Methods 0.000 description 9
- 210000005245 right atrium Anatomy 0.000 description 9
- 230000002861 ventricular Effects 0.000 description 9
- 238000013194 cardioversion Methods 0.000 description 8
- 208000028867 ischemia Diseases 0.000 description 8
- 206010067171 Regurgitation Diseases 0.000 description 7
- 206010003119 arrhythmia Diseases 0.000 description 7
- 210000003748 coronary sinus Anatomy 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 208000031225 myocardial ischemia Diseases 0.000 description 7
- 238000002633 shock therapy Methods 0.000 description 7
- 210000002620 vena cava superior Anatomy 0.000 description 7
- 230000006793 arrhythmia Effects 0.000 description 6
- 230000001746 atrial effect Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000035939 shock Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 210000003709 heart valve Anatomy 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000005246 left atrium Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- 206010061216 Infarction Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 210000003129 brachiocephalic vein Anatomy 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 239000004020 conductor Substances 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- WABPQHHGFIMREM-NOHWODKXSA-N lead-200 Chemical compound [200Pb] WABPQHHGFIMREM-NOHWODKXSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000005236 sound signal Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 206010047302 ventricular tachycardia Diseases 0.000 description 3
- 208000012868 Overgrowth Diseases 0.000 description 2
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 2
- 206010071186 Ventricular dyssynchrony Diseases 0.000 description 2
- 230000007175 bidirectional communication Effects 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000002837 heart atrium Anatomy 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000004007 neuromodulation Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 201000000057 Coronary Stenosis Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 206010011089 Coronary artery stenosis Diseases 0.000 description 1
- 101000607909 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 1 Proteins 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 102100039865 Ubiquitin carboxyl-terminal hydrolase 1 Human genes 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 208000011316 hemodynamic instability Diseases 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- ODNHQUQWHMGWGT-UHFFFAOYSA-N iridium;oxotin Chemical compound [Ir].[Sn]=O ODNHQUQWHMGWGT-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- -1 polytetrafluoroethylene Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000718 qrs complex Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B7/00—Instruments for auscultation
- A61B7/02—Stethoscopes
- A61B7/04—Electric stethoscopes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
- A61N1/36585—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by two or more physical parameters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/021—Measuring pressure in heart or blood vessels
- A61B5/0215—Measuring pressure in heart or blood vessels by means inserted into the body
- A61B5/02158—Measuring pressure in heart or blood vessels by means inserted into the body provided with two or more sensor elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/024—Detecting, measuring or recording pulse rate or heart rate
- A61B5/0245—Detecting, measuring or recording pulse rate or heart rate by using sensing means generating electric signals, i.e. ECG signals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B7/00—Instruments for auscultation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
- A61N1/36514—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure
- A61N1/36564—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure controlled by blood pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
- A61N1/36514—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure
- A61N1/36578—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure controlled by mechanical motion of the heart wall, e.g. measured by an accelerometer or microphone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/12—Arrangements for detecting or locating foreign bodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/48—Diagnostic techniques
- A61B6/486—Diagnostic techniques involving generating temporal series of image data
- A61B6/487—Diagnostic techniques involving generating temporal series of image data involving fluoroscopy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/056—Transvascular endocardial electrode systems
Definitions
- the disclosure relates generally to medical devices and, in particular, to a heart sound recording apparatus and method for monitoring cardiac function.
- Heart sounds contain a great deal of diagnostic information.
- a stethoscope is a standard instrument used in clinical examinations and has aided in enabling clinicians to become familiar with normal and abnormal heart and lung sounds.
- Clinicians typically refer to four heart sounds, S 1 , S 2 , S 3 and S 4 .
- the first heart sound, S 1 corresponds to the start of ventricular systole and is generated by the abrupt closure of the mitral and tricuspid valves between the ventricles and atria as ventricular pressure exceeds atrial pressure.
- the second heart sound, S 2 is generated by the closure of the aortic and pulmonary valves, near the end of ventricular systole and start of ventricular diastole.
- the third heart sound, S 3 is associated with early, passive diastolic filling of the ventricles
- the fourth heart sound, S 4 is associated with late, active filling of the ventricles due to atrial contraction.
- the third sound is generally difficult to hear in a normal patient using a stethoscope, and the fourth sound is generally not heard in a normal patient. Presence of the third and fourth heart sounds may indicate a pathological condition.
- FIG. 1 is a functional block diagram of an IMD system for acquiring acoustical signals for monitoring cardiac function.
- FIG. 2 is a functional block diagram of the IMD shown in FIG. 1 .
- FIG. 3A is a view of a distal portion of an acoustical sensing lead incorporating a hydrophone according to one embodiment.
- FIG. 3B is an enlarged sectional view of another example of a lead carrying a hydrophone for sensing cardiac and blood-flow related signals.
- FIG. 3C is an enlarged sectional view of a distal tip of a lead carrying a hydrophone according to another embodiment.
- FIG. 4A is a schematic view of an acoustical sensing lead carrying multiple hydrophones according to one embodiment.
- FIG. 4B is a schematic illustration of a lead carrying hydrophones for directional sensing of cardiac and blood flow related sounds.
- FIG. 4C is a cut-away view of a patient heart depicting an RV lead carrying hydrophones for directional sensing of heart and blood flow sounds.
- FIG. 5 is a flow chart of a method for monitoring cardiac function using an implantable medical device system including hydrophones.
- FIG. 6 is a flow chart of one method for using hydrophone signals for controlling shock therapy.
- FIG. 7 is a flow chart of a method for monitoring heart failure using implantable hydrophones.
- FIG. 8 is a flow chart of one method for detecting acute myocardial infarction (AMI) according to one embodiment.
- FIG. 9 is a flow chart of a method for monitoring for hypertension using hydrophone signals.
- module refers to an application specific integrated circuit (ASIC), an electronic circuit, a processor (shared, dedicated, or group) and memory that execute one or more software or firmware programs, a combinational logic circuit, or other suitable components that provide the described functionality.
- ASIC application specific integrated circuit
- processor shared, dedicated, or group
- memory that execute one or more software or firmware programs, a combinational logic circuit, or other suitable components that provide the described functionality.
- FIG. 1 is a functional block diagram of an IMD system 100 for acquiring acoustical signals for monitoring cardiac function.
- System 100 includes IMD 10 coupled to leads 118 , 120 , and 122 which carry multiple electrodes for sensing cardiac EGM signals and/or delivering cardiac pacing pulses.
- IMD 10 is configured for bidirectional communication with programmer 170 .
- IMD 10 may be, for example, an implantable pacemaker, cardiovertor, and/or defibrillator that provides electrical signals to heart 112 via electrodes coupled to one or more of leads 118 , 120 , and 122 .
- Each of leads 118 , 120 and 122 is shown carrying a hydrophone 190 , 192 , and 194 for use in sensing cardiac function as will be described in greater detail below.
- the hydrophones 190 , 192 , and 194 are adapted for positioning directly in the blood stream and are deployed to a desired sensing location for monitoring specific cardiac or blood flow sounds at selected frequencies to obtain acoustical signals correlated to cardiac or hemodynamic function.
- the hydrophones 190 , 192 , and 194 are configured to receive acoustical signals through an opening in the lead body of the respective leads 118 , 120 and 122 and generate an electrical signal representative of sounds produced at a targeted location along a patient's cardiovascular system.
- An outer surface of the elongated lead body of each of leads 118 , 120 and 122 may include a shaped contour for directing the opening in the lead body for receiving the sounds from a direction of the targeted location.
- a shaped contour of the outer surface of the lead body may include a pre-shaped curve or bend of the lead body, a recessed surface, or a convex or spherical surface.
- the opening may extend along the shaped contour, i.e. along a pre-shaped curve, and/or along a recessed surface or along a convex surface.
- the opening may alternatively extend along the outer surface of the lead body proximally or distally to a pre-shaped curve for directing the opening toward a targeted cardiovascular location for receiving sounds generated at the targeted location.
- the lead body opening and associated hydrophone receiving sound signals through the opening may be positioned along an outer side surface of the lead body as generally shown in FIG. 1 .
- an opening and associated hydrophone may be positioned along an outer surface of the distal tip of the lead body.
- the hydrophone and the lead body may be hermetically sealed to prevent influx of body fluids into the lead body and into the hydrophone.
- Various embodiments of a lead carrying a hydrophone and having an outer surface including a shaped contour for directing an opening toward a targeted sound source to enable directional sensing of cardiovascular sounds by a hydrophone will be further described in detail in conjunction with FIGS. 3A through 4C .
- IMD 10 is shown configured for multi-chamber pacing and sensing in the right atrium (RA) 126 , the right ventricle (RV) 128 , and the left ventricle (LV) 132 using leads 118 , 120 and 122 .
- the system shown is configured for delivering cardiac resynchronization therapy (CRT) for treating heart failure in patient 114 according to one embodiment.
- IMD 10 may additionally or alternatively be configured for detecting cardiac arrhythmias and delivering arrhythmia therapies, such as anti-tachycardia pacing therapy and cardioversion/defibrillation shocks.
- IMD 10 is one example of numerous types of devices that an acoustical signal sensing system and associated methods for monitoring cardiac conditions as described herein may be implemented. Such devices may be capable of delivering a therapy including one or more of cardiac pacing, neurostimulation, or fluid delivery for administering a pharmacological agent or biological fluid.
- an IMD system including acoustical signal monitoring may be provided as a monitoring-only system which acquires and analyzes acoustical signals for diagnostic and prognostic purposes without having therapy delivery capabilities.
- a device for performing the methods described herein is not limited to fully implantable medical devices but may be implemented using external components coupled to implantable leads or catheters carrying at least one hydrophone positioned in the blood stream and thus may include a combination of implantable and external components.
- the system 100 shown in FIG. 1 is one illustrative embodiment of a system in which a hydrophone and associated methods described herein may be implemented.
- IMD 10 delivers RV pacing pulses and senses RV intracardiac EGM signals using RV tip electrode 140 and ring electrode 142 positioned in the RV 128 .
- RV lead 118 is shown to carry a coil electrode 162 which may be used for delivering high voltage cardioversion or defibrillation shock pulses.
- IMD 10 senses LV EGM signals and delivers LV pacing pulses using the electrodes 144 carried by a multipolar coronary sinus lead 120 , extending through the right atrium (RA) 126 and into a cardiac vein 130 via the coronary sinus.
- coronary sinus lead 120 may include electrodes positioned along the left atrium (LA) 136 for sensing left atrial EGM signals and deliver LA pacing pulses.
- LA left atrium
- IMD 10 senses RA EGM signals and delivers RA pacing pulses using RA lead 122 , carrying tip electrode 148 and ring electrode 150 .
- RA lead 122 is shown carrying a coil electrode 166 which may be positioned along the superior vena cava (SVC) for use in delivering cardioversion/defibrillation shocks.
- RV lead 118 carries both the RV coil electrode 162 and the SVC coil electrode 166 .
- IMD 10 is shown in a right pectoral implant position in FIG. 1 , a more typical implant position, particularly when IMD 10 is embodied as an ICD, may be a left pectoral implant position.
- IMD 10 includes internal circuitry for performing the functions attributed to IMD 10 and a housing 160 encloses the internal circuitry. It is recognized that the housing 160 or portions thereof may be configured as an active electrode for use in cardioversion/defibrillation shock delivery or used as an indifferent electrode for unipolar pacing or sensing configurations.
- IMD 10 includes a connector block 134 having connector bores for receiving proximal lead connectors of leads 118 , 120 and 122 . Electrical connection of electrodes carried by leads 118 , 120 and 122 and IMD internal circuitry is achieved via various connectors and electrical feedthroughs included in connector block 134 .
- IMD 10 may provide acoustical signal data to programmer 170 via wireless telemetry. Acoustical signal data and/or an alarm or alert relating to a detected cardiac condition may be transmitted to programmer 170 for display or further transmission to a user via a communication network. Acoustical signal monitoring procedures may be performed automatically by IMD 10 according to a monitoring protocol or upon a user request using programmer 170 . A patient or physician alert and/or therapy adjustments may be made automatically by IMD 10 in response to acoustical signal analysis. Alternatively, acoustical signals may be obtained by IMD 10 and transmitted to programmer 170 for analysis and display of results to a user.
- Programmer 170 includes a display 172 , a processor 174 , a user interface 176 , and a communication module 178 including wireless telemetry circuitry for communication with IMD 10 .
- programmer 170 may be a handheld device or a microprocessor based home monitor or clinical programming device.
- a user such as a physician, technician, nurse or other clinician, may interact with programmer 170 to communicate with IMD 10 .
- the user may interact with programmer 170 via user interface 176 to retrieve physiological or diagnostic information from IMD 10 .
- a user may also interact with programmer 170 to program IMD 10 , e.g., select values for operational parameters of the IMD.
- a user interacting with programmer 170 may request IMD 10 to perform an acoustical signal analysis algorithm or request data stored by IMD 10 relating to acoustical signals.
- Processor 174 receives data from IMD 10 for use in generating a display presented on display 172 including information relating to acoustical data and any notifications or alert messages.
- Programmer 170 includes a communication module 178 to enable wireless communication with IMD 10 .
- Examples of communication techniques used by system 100 include low frequency or radiofrequency (RF) telemetry, which may be an RF link established via Bluetooth, WiFi, or MICS.
- programmer 170 may include a programming head that is placed proximate the IMD 10 to establish and maintain a communication link, and in other examples programmer 170 and IMD 10 may be configured to communicate using a distance telemetry algorithm and circuitry that does not require the use of a programming head and does not require user intervention to maintain a communication link.
- RF radiofrequency
- programmer 170 may be coupled to a communications network via communications module 178 for transferring data to a remote database or computer to allow remote management of the patient 114 using the acoustical signal monitoring described herein.
- Remote patient management systems may be configured to utilize the presently disclosed techniques to enable a clinician to review data derived from acoustical signals and authorize programming of IMD control parameters.
- acoustical signals or parameters derived from the signals may be transferred from programmer 170 to a clinic or other expert center for review. The clinician or other expert may then authorize programming of the IMD for delivering or adjusting a therapy via a communications network and programmer 170 .
- FIG. 2 is a functional block diagram of IMD 10 shown in FIG. 1 .
- IMD 10 includes an acoustical sensing module 12 coupled to one or more acoustical sensors 11 , cardiac EGM signal sensing circuitry 14 and therapy delivery module 15 both coupled to electrodes 13 , control processor 16 and associated memory 18 , and telemetry circuitry 20 .
- Acoustical sensing module 12 receives signals from acoustical sensors 11 for sensing acoustical signals which are provided to control processor 16 .
- Acoustical sensing module 12 is configured to receive signals from sensors 11 embodied as hydrophones for sensing acoustical signals from one or more targeted locations in the heart or blood vessels.
- acoustical sensing module 12 may include multiple “channels” configured to particularly sense specific cardiac sounds based on sensing location and/or frequency.
- EGM sensing circuitry 14 may be used by control processor 16 to set sensing windows used by acoustical sensing module 12 for sensing acoustical signals during the cardiac cycle.
- Acoustical sensing module 12 may include one or more sense amplifiers, filters and rectifiers for optimizing a signal-to-noise ratio and obtaining acoustical signals useful for deriving parameters used for monitoring cardiovascular function. Separate and unique amplification and filtering properties may be provided for sensing different acoustical signal channels to improve signal quality as needed.
- Acoustical sensors 11 are implemented as hydrophones which are positioned transvenously, within a vein, artery or heart chamber and may correspond to the sensors 190 , 192 , and 194 shown in FIG. 1 , or any other hydrophones shown herein.
- one or more leads positioned in a patient's blood stream may carry one or more sensors as will be further described herein.
- switching circuitry 26 may be used to control which acoustical sensors, or which transducers within a sensor, are coupled to sensing module 12 .
- An electrical signal produced by the sensor(s) representative of sounds or vibrations produced by the heart or blood is processed, which may include digital conversion, to derive acoustical signal parameters, such as amplitude content, frequency content, relative time intervals, or the like as derived by acoustical sensing module 12 and/or control processor 16 .
- EGM sensing circuitry 14 coupled to at least one sensing electrode pair included in electrodes 13 , is provided to sense cardiac signals, e.g. P-wave and/or R-wave signals attendant to the depolarization of the atria and ventricles of the heart, respectfully.
- EGM sensing circuitry 14 is coupled to electrodes 13 , which may include transvenous intracardiac electrodes or epicardial electrodes for sensing cardiac EGM signals.
- cardiac electrical signals may be sensed using subcutaneous or submuscular electrodes for sensing ECG signals.
- ECG signals and EGM signals are referred to herein generally as “cardiac electrical signals”.
- Electrodes 13 may correspond to the electrodes 140 , 142 , 144 , 148 , 150 162 and 166 shown in FIG. 1 but may include fewer or more electrodes positioned in operative relation to one or more heart chambers.
- Cardiac electrical signals may be used for timing sensing windows used by acoustical sensing module 12 for obtaining acoustical signals.
- Cardiac electrical signals may additionally or alternatively be used by control processor 16 for timing therapy delivery, such as electrical stimulation pulses during CRT or other pacing therapy, e.g. according to programmed pacing intervals, such as a programmed atrial-ventricular (AV) interval and/or inter-ventricular (VV) interval.
- AV atrial-ventricular
- VV inter-ventricular
- Therapy delivery module 15 is provided for delivering pacing pulses to the patient's heart via electrodes 13 using programmable pacing parameters. Electrodes 13 used for delivering pacing pulses may include dedicated pacing electrodes, or may include shared pacing and sensing electrodes. Switching circuitry may be included in therapy delivery module 15 and sensing module 14 for selecting which electrodes 13 are coupled to EGM sensing circuitry 14 and which electrodes are coupled to therapy delivery module 15 as well as the polarity of such electrodes. While two electrodes are shown coupled to therapy delivery module 15 and two electrodes are shown coupled to EGM sensing module 14 in FIG. 2 , it is recognized that multiple sensing and pacing channels corresponding to multiple heart chambers may require multiple electrodes coupled to each of sensing module 14 and therapy delivery module 15 and such connections may be controlled by a switching circuit.
- Therapy delivery module 15 is controlled by control processor 16 to deliver pacing pulses according to a therapy delivery algorithm.
- Control processor 16 receives signals from EGM sensing circuitry 14 for use in controlling therapy delivery module 15 to deliver appropriately timed pacing pulses and/or cardioversion/defibrillation shock pulses.
- neurostimulation may be delivered.
- therapy delivery module may include a fluid pump for delivering a drug for treating a detected condition.
- an automatically delivered therapy may be started, stopped or adjusted by control processor 16 in response to parameters derived from acoustical signals.
- Control processor 16 may include any one or more of a microprocessor, a digital state machine, a digital signal processor (DSP), an application specific integrated circuit (ASIC), a field-programmable gate array (FPGA), or equivalent discrete or integrated logic circuitry.
- processor 16 may include multiple components, such as any combination of one or more microprocessors, one or more controllers, one or more DSPs, one or more ASICs, or one or more FPGAs, as well as other discrete or integrated logic circuitry.
- the functions attributed to control processor 16 herein may be embodied as software, firmware, hardware or any combination thereof, implemented in a single device or distributed across two or more devices, which may include one or more implantable devices, external devices, or a combination of both.
- Control processor 16 includes an acoustical signal analysis module 22 for analyzing acoustical signals obtained by sensing module 12 .
- the analysis module 22 includes circuitry and/or computer-readable instructions for performing an algorithm for deriving parameters and/or trends or relative changes in parameters derived from the acoustical signals.
- Memory 18 stores algorithms used by control processor 16 for performing monitoring procedures. Such algorithms may include monitoring protocols for acquiring acoustical signals as well as controlling therapy response and/or triggering patient or clinician alert generation. Memory 18 may also be used to store other data and information used by control processor 16 for controlling device functions, including a pacing or neurostimulation therapy delivered by therapy delivery module 15 , controlling sensing functions by EGM sensing circuitry 14 , controlling telemetry module 20 , and controlling patient alert 24 in response to detecting an alert condition based on acoustical signals and cardiac electrical signals. Alerts or notifications may be triggered by control processor 16 in response to acoustical signal measurements and transmitted to an external programmer via telemetry 20 . Alternatively or additionally, a patient alert module 24 may generate audible sounds, a vibration, electrical stimulation to cause muscle twitching, or other alert signal perceivable by the patient.
- a patient alert module 24 may generate audible sounds, a vibration, electrical stimulation to cause muscle twitching, or other alert signal
- Memory 18 may include computer-readable instructions that, when executed by processor 16 , cause IMD 10 and processor 16 to perform various functions attributed throughout this disclosure to IMD 10 and processor 16 .
- the computer-readable instructions may be encoded within memory 18 .
- Memory 18 may comprise computer-readable storage media including any volatile, non-volatile, magnetic, optical, or electrical media, such as a random access memory (RAM), read-only memory (ROM), non-volatile RAM (NVRAM), electrically-erasable programmable ROM (EEPROM), flash memory, or any other digital media with the sole exception being a transitory, propagating signal.
- RAM random access memory
- ROM read-only memory
- NVRAM non-volatile RAM
- EEPROM electrically-erasable programmable ROM
- flash memory or any other digital media with the sole exception being a transitory, propagating signal.
- IMD 10 may include or be coupled to other sensors 28 which provide signals to control processor 16 correlated to other physiological conditions of the patient.
- Sensors 28 may include an activity sensor, posture sensor, pressure sensor, oxygen sensor, temperature sensor, impedance sensor or the like. Sensor signals may be used by control processor 16 in detecting a physiological condition of the patient indicating a need to provide or adjust therapy or generate a patient alert.
- Telemetry module 20 is configured for bidirectional communication with an external programmer 170 or computer operating software for programming the IMD 10 .
- Control processor 16 may generate acoustical data and information relating to a monitored condition that is transmitted to an external device via telemetry module 20 for review by a clinician.
- functions attributed herein to control processor 16 may be performed across one or more processors that may include an external processor receiving data from telemetry module 20 , such as processor 174 of external programmer 170 .
- FIG. 3A is a view of a distal portion of an acoustical sensing lead 200 incorporating a hydrophone according to one embodiment.
- Lead 200 includes an elongated lead body 202 having a curve or bend 204 imposing a substantially “J”-shaped distal portion of the lead body 202 .
- a pre-formed shape or curve of lead body 202 can provide a desired directionality of a hydrophone for “listening” to targeted cardiac sounds or blood flow at particular cardiovascular locations.
- lead 200 is shown including two hydrophones 210 and 220 .
- Hydrophone 210 is positioned at the distal lead end 206 which can be positioned for receiving sounds from a particular direction corresponding to sound source A due to the J-shape.
- a second hydrophone 220 may be positioned along an outer diameter of a curve 220 to enable hydrophone 220 to receive sounds primarily from a different direction(s) than hydrophone 210 .
- the hydrophones 210 and 220 may be oriented to receive acoustical signals from approximately opposite directions, for example from source A and source B, respectively.
- one or more hydrophones may be carried by a preformed lead body having a particular shape designed to orient the hydrophone(s) for receiving sounds from specific directions for acoustical sensing from one or more targeted sources.
- Hydrophone 210 includes a hermetically-sealed housing 216 .
- a thin diaphragm or membrane 214 extends along an exposed portion of housing 216 and an array of acoustical transducers 212 are positioned along the diaphragm 214 within the housing 216 .
- the exposed portion of housing 216 may be substantially flat or having a concave, conical or spherical surface to facilitate directional sensing of acoustical signals.
- the housing 216 may include a radio-opaque material such that the direction that the sensor 210 is facing relative to a patient's cardiovascular anatomy may be determined under fluoroscopy or x-ray.
- sensor 220 includes a housing 226 mounted within lead body 202 and enclosing acoustical transducers 222 a and 222 b (collectively “ 222 ”).
- a thin diaphragm or membrane 224 extends over acoustical transducers 222 , such that transducers 222 are hermetically sealed within lead body 202 .
- Sensor 220 is shown to include a reference mark 228 which may be provided as radio-opaque material along housing 226 for indicating the directionality of sensor 220 during an implantation or re-positioning procedure.
- Acoustic transducer arrays 212 and 222 are embodied as piezoceramic transducers in one embodiment.
- the arrays 212 and 222 include two or more transducers of different sizes or other differing properties for providing sensitivity at different selected frequencies.
- the piezoceramic transducers may range from one to several millimeters in size to obtain signals responsive to a narrow band of frequencies from an overall range of sound frequencies from 10 Hz to 10 kHz.
- piezoceramic materials (or films) each having different frequency responses can be packed parallel to sense different sound frequencies.
- individual transducers may be built to have different frequency ranges of 10-100 Hz, 100-1000 Hz, 1000-10 KHz and so on.
- the acoustic transducers may include a membrane capsule transducer or iridium tin oxide (ITO).
- ITO iridium tin oxide
- Individual ITO transducers included in an array of transducers may range from tens of micrometers to one millimeter in width with a thickness of 100 nm to 1000 nm for obtaining different sound frequencies.
- the transducer arrays 212 is depicted in a linear arrangement in FIG. 3A , but may alternatively be arranged circumferentially or in other patterns relative to one another.
- a hydrophone By placing multiple transducers responsive to different resonant frequencies within a hydrophone, different aspects of blood flow, blood pressure, and cardiac function such as wall motion and relaxation or valve closure and opening, may be monitored using sounds received from a targeted direction and in a targeted frequency range. For example, different frequency components of sound due to valve opening and closure may be examined to detect a change in blood pressure or cardiac function. Changes in power of the acoustical signal in different frequency ranges may be indicative of a change in blood flow pattern due to a change in a cardiac condition.
- One or more piezoelectric transducers included in an acoustical sensor may be positioned within the sensor with its piezoelectric axis aligned in parallel with a direction of targeted sound source.
- each of the transducers 212 is arranged with its piezoelectric axis aligned with or parallel to a direction of targeted sound source A, as indicated by the arrows extending through transducers 212 .
- the transducers 212 will be less sensitive or insensitive to sounds arriving from directions that are not parallel to the aligned piezoelectric axes of the transducers 212 .
- Transducer 222 a is positioned with its piezoelectric axis oriented in a first direction, as indicated by the arrow extending through transducer 222 a, and transducer 222 b is positioned with its piezoelectric axis oriented in a second direction, as indicated by the arrow extending through transducer 222 b, that is different than the first direction.
- Transducer 222 a is positioned with its piezoelectric axis oriented in a direction that is substantially parallel to the direction of targeted sound source B.
- Transducer 222 b is positioned with its associated piezoelectric axis substantially parallel to the direction of a different targeted sound source C.
- a given piezoelectric transducer will be less sensitive or insensitive to sounds arriving from a source that is in a direction from the transducer that is substantially orthogonal to the piezoelectric axis.
- directional sensitivity of an acoustical sensor includes a selected orientation of a piezoelectric axis of one or more transducers in some embodiments.
- FIG. 3B is an enlarged sectional view of another example of a lead 250 carrying a hydrophone for sensing cardiac and blood-flow related signals.
- Lead 250 includes an elongated lead body 251 having an outer side 252 .
- a hydrophone 260 which may include multiple transducers 262 responsive to distinct frequency ranges, is fixed along an opening 253 along an outer side 252 of the lead body 251 .
- the opening 254 is shown formed along a recessed surface 254 of outer side 252 , extending between a side wall 256 .
- a raised flange 258 may surround the recessed surface 254 , raising the height of side wall 256 .
- the outer surface 263 of hydrophone 260 is hermetically sealed by a thin, biocompatible membrane or coating.
- a thin film or coating of polyurethane, polytetrafluoroethylene (PTFE), silicone medical adhesive, or other blood compatible coatings or layers, which may include a bioactive layer or a layer that promotes cellular overgrowth, such as endothelial cell overgrowth may be applied over outer surface 263 .
- Transducers 262 are mounted along a hybrid circuit board 264 or other substrate which enables fixation of hydrophone 260 along lead body 251 and electrical connection to individual conductors 266 electrically coupled to each of transducers 262 .
- Hybrid circuit board 264 and/or conductors 266 may include filters and amplifiers 268 for filtering and amplification of each transducer signal according to distinct filtering and amplification properties selected for each distinct frequency range of the individual transducers 262 .
- FIG. 3C is an enlarged sectional view of a distal tip of a lead 270 according to another embodiment.
- Lead body 271 terminates at a distal tip 272 that is substantially spherical in shape, i.e. tip 272 is rounded forming a portion of a sphere.
- An opening 273 formed in the spherical tip 272 exposes one or more transducers 282 included in hydrophone 280 .
- the exposed outer surface of hydrophone 280 is hermetically sealed along lead tip 272 by a coating or thin layer of a biocompatible material such as polyurethane or silicone as described above.
- positioning a hydrophone along a recessed surface (as shown in FIG. 3B ) or a rounded, conical or spherical surface of a lead body can provide greater directional sensitivity of the hydrophone.
- the transducers 282 are mounted on a substrate 284 , which may be a hybrid circuit board, which enables hydrophone 280 to be fixedly coupled within lead body 271 at distal tip 272 .
- Transducers 282 are electrically coupled to individual conductors 286 via substrate 284 for carrying each transducer signal back to the acoustic sensing module 12 of the associated IMD.
- Each transducer 282 may be provided with unique filtering and amplification 288 .
- FIG. 4A is a schematic view of an acoustical sensing lead 300 according to one embodiment.
- Lead 300 includes an elongated lead body 302 carrying multiple hydrophones 304 A through 304 D.
- Each hydrophone may include one or more transducers to provide acoustical sensitivity in multiple frequency ranges.
- Each hydrophone 304 A- 304 D may be positioned for sensing acoustical signals from a particular direction at different anatomical locations.
- hydrophones 304 A- 304 D may be spaced along lead body 302 such that when lead 300 is deployed along a blood vessel or the heart, each hydrophone 304 A- 304 D is positioned at a particular level and location along a heart chamber or blood vessel to receive sounds from a targeted location.
- lead 300 is provided as a coronary sinus lead adapted for advancement through the coronary sinus and along a cardiac vein for positioning hydrophones 304 A- 304 D at different locations along the patient's heart.
- Hydrophones 304 A- 304 D can be positioned at different levels along the heart, e.g. along the left atrium, the mitral valve, the aortic valve, or the left lateral free wall along a mid-portion of the left ventricle.
- Openings along lead body 302 through which hydrophones 304 A- 304 D receive sound waves may be defined in different directions for each of hydrophones 304 A- 304 D to provide directional sensitivity of each hydrophone.
- one hydrophone may be directed toward the aortic valve and one hydrophone may be directed toward the mitral valve.
- a J-shaped lead as shown in FIG. 3 may be positioned in the right ventricle to direct a hydrophone for receiving signals from the direction of the mitral valve and a coronary sinus lead having multiple hydrophones may be positioned along a cardiac vein to direct at least one hydrophone in the direction of the aortic valve.
- a lead in the right ventricle may carry a hydrophone directed toward the pulmonary valve and a coronary sinus lead may carry a hydrophone directed toward the aortic valve. Collection of directionally sensitive acoustical signals allows changes in opening and closing times between the two valves to be closely monitored.
- a lead carrying a hydrophone may additionally carry other sensors or electrodes allowing multiple physiological signals to be acquired using the same lead.
- a lead may carry electrodes for sensing cardiac EGM signals in addition to sensing acoustical signals to enable analysis of correlation between electrical cardiac activity and mechanical cardiac activity.
- FIG. 4B is a schematic illustration of a lead 350 carrying hydrophones for directional sensing of cardiac and blood flow related sounds.
- Lead 350 is shown carrying two hydrophone sensors 368 and 378 , which may each respectively include one or more transducers designed to sense different frequency ranges.
- Lead 350 includes an elongated lead body 352 having a distal end 354 and outer side 356 .
- Outer side 356 includes a recessed surface 360 surrounded by a sidewall 362 .
- Sidewall 362 may extend in a generally circular, oval or rectangular shape around recessed surface 360 .
- Recessed surface 360 and sidewall 362 promote directional sensitivity of hydrophone 368 .
- Recessed surface 360 is shown to be concave in FIG. 4B , but may be substantially flat or convex in other embodiments.
- Sidewall 362 extends from outer surface 356 to recessed surface 360 .
- Lead body 350 may further include a raised lip, rim, or flange 366 along an edge of sidewall 362 defining opening 364 .
- the protruding flange 366 extends sidewall 362 radially outward from outer side 356 and deflects sound waves not in approximate alignment with recessed surface 360 .
- Sidewall 362 is shown to be substantially vertical, i.e. perpendicular to outer side 356 . In other embodiments sidewall 362 may be angled with respect to outer side 356 and surface 360 .
- Hydrophone 368 will be more sensitive to sound waves generated by a source at location B than at A or C due to the recessed, concave surface 360 along which hydrophone 368 is mounted. Sound waves traveling directly from sources A and C toward lead body 352 will be reflected or obstructed by flange 366 . Sound or vibrations reaching hydrophone 368 from sources not in approximate alignment with opening 364 and recessed surface 360 will be substantially diminished compared to a configuration in which hydrophone 368 is positioned along a non-recessed portion of outer side 356 . In this way, a recessed surface 360 and sidewall 362 formed along an outer side 356 of lead body 350 promotes greater sensitivity of sounds produced by specific structures or at specific locations in the heart or blood vessels. In other examples, lead body 352 may be formed with multiple recessed surfaces formed at different radial and longitudinal locations along outer side 356 to hold hydrophones for receiving sounds from different preferential directions.
- Hydrophone 378 is shown positioned at distal lead end 354 along a substantially flat recessed surface 370 .
- Sidewall 372 defines a conical opening 374 through which hydrophone receives sounds from a preferential direction D. Sounds arriving from sources A, B and C will be deflected away from hydrophone 378 .
- sidewall 372 is shown angled with respect to a substantially flat recessed surface 370 . It is contemplated that in other embodiments, a hydrophone positioned at a distal lead end may be positioned along a concave or convex recessed surface extending between a substantially perpendicular or angled surrounding sidewall.
- FIG. 4C is a cut-away view of a patient heart depicting an RV lead 320 carrying hydrophones for directional sensing of heart and blood flow sounds.
- Lead 320 is a substantially J-shaped lead carrying a proximal hydrophone 322 , a more distal hydrophone 324 , and a distal tip hydrophone 326 .
- Proximal hydrophone 322 and more distal hydrophone 324 are positioned along the outer side of the lead body 332 , for example in a manner similar to sensor 368 shown in FIG. 4B .
- Distal tip hydrophone 326 is located in the distal tip of lead 320 , for example in a manner similar to sensor 378 shown in FIG. 4B .
- Proximal hydrophone 322 is located along an outer side of the lead body 332 such that it is positioned at the level of the superior vena cava (SVC) when the distal tip 330 is fully advanced into the RV. Positioned in the SVC, proximal hydrophone 322 can be directed toward the aorta 340 for receiving blood flow sounds in the aorta. As will be described below, blood flow sounds in the aorta may be analyzed to detect changes in blood flow velocity for use in detecting a cardiac condition. In alternative embodiments, a hydrophone may be positioned along the innominate vein for sensing blood flow sounds in the adjacent aorta.
- SVC superior vena cava
- Distal hydrophone 324 is positioned along the outer side of the lead body 332 such that it can be directed toward the pulmonary valve (PV) 342 when the lead distal tip 330 is fully advanced into the RV. Hydrophone 324 is positioned along the outer side corresponding to the inside curve of the “J” shaped bend of lead 320 . Hydrophone 324 can be positioned to generate a signal with preferential sensitivity to pulmonary valve sounds and thereby generate a signal highly correlated to sounds produced by pulmonary valve opening and closure. When configured along a recessed surface of lead body 332 as described above, with or without a surrounding protruding flange, hydrophone 324 will be less sensitive to sounds or vibrations arriving from other structures such as the tricuspid valve 344 .
- Distal tip hydrophone 326 is located at the tip 330 of the J-shaped distal end of lead 320 such that it faces back toward the tricuspid valve 344 through which the lead 320 is advanced into the RV from the RA. Being within a recess of lead tip 330 surrounded by a sidewall as described in conjunction with FIG. 4 b, hydrophone 326 will be preferentially sensitive to sounds produced by the opening and closure of the tricuspid valve 344 and less sensitive to sounds produced by other structures, such as the pulmonary valve 342 .
- This illustrative embodiment provides three hydrophones carried by a single lead body configured to preferentially sense acoustical signals from three different target sources, the aorta, the pulmonary valve and the tricuspid valve. It is recognized that numerous configurations and variations exist for deploying one or more hydrophones to particular locations, carried by one or more leads and each directed toward a preferential source of sound or vibration associated with cardiac function and blood flow.
- lead 320 may be provided with one or more fixation members along lead body 320 to anchor the lead body at a desired location and to maintain a desired position and directional orientation of hydrophones 322 , 324 , and 326 .
- fixation members may be located along the curve of the J-shaped portion of the lead, at a distal end of the lead, or at proximal locations for anchoring the lead and respective hydrophones at desired locations.
- FIG. 5 is a flow chart 400 of a method for monitoring cardiac function using an implantable medical device system including hydrophones.
- Flow chart 400 is intended to illustrate the functional operation of the device, and should not be construed as reflective of a specific form of software or hardware necessary to practice the methods described. It is believed that the particular form of software, firmware and hardware will be determined primarily by the particular system architecture employed in the device and by the particular detection and therapy delivery methodologies employed by the device. Providing software to accomplish the described functionality in the context of any modern IMD, given the disclosure herein, is within the abilities of one of skill in the art.
- Non-transitory computer-readable medium includes instructions for causing a programmable processor to carry out the methods described.
- a “non-transitory computer-readable medium” includes but is not limited to any volatile or non-volatile media, such as a RAM, ROM, CD-ROM, NVRAM, EEPROM, flash memory, or other computer-readable media, with the sole exception being a transitory, propagating signal.
- the instructions may be implemented as one or more software modules, which may be executed by themselves or in combination with other software.
- multiple implantable hydrophones are implanted at desired locations for targeted acoustical sensing.
- hydrophones are positioned for sensing mitral valve sounds, aortic valve sounds, tricuspid valve sounds, pulmonary valve sounds, LV free wall motion, and blood flow in the aorta or another major artery.
- rhythm stability analysis is performed.
- Rhythm stability analysis is performed to detect a shockable rhythm at block 412 .
- rhythm stability analysis may include analysis of synchrony between electrical events and mechanical events and/or between mechanical events identified using signals received from the hydrophones.
- a shockable rhythm is detected at block 412 based on fast electrical events and a low correlation between electrical and mechanical events or other changes in the hydrophone signals.
- Processor 16 makes a therapy decision and/or generates an alert at block 420 .
- a cardioversion/defibrillation shock therapy may be delivered at block 420 in response to detecting a shockable rhythm based on signals received from the hydrophone(s). Additional details regarding using hydrophone signals for controlling a shock therapy are presented in conjunction with FIG. 6 .
- Contractility analysis is performed at block 408 .
- Analysis to detect changes in myocardial contractility may include measuring the power and frequency content of a hydrophone signal(s) directed toward the pulmonary and/or aortic valves or mitral and tricuspid valves, the appearance of S 3 -related sounds, or changes in blood flow as detected by an increase in frequency components correlated to slow blood flow.
- a hydrophone may be advanced transvenously and placed directionally toward an artery extending adjacent to the vein.
- a hydrophone positioned in the superior vena cava or the innominate vein may be directed for preferential sensing of blood flow sounds in the aorta. The sound or vibration caused by blood flow in the artery is then sensed.
- the senor is placed near a bifurcation or an origin of an artery branch.
- the vibration or sound caused by blood flow will be correlated to the blood flow velocity or turbulence and/or blood pressure in the artery.
- a surrogate measure of blood flow velocity may be obtained.
- Worsening myocardial contractility may be responded to at block 420 by delivering a therapy and/or generating a patient or physician alert.
- a therapy delivered in response to worsening myocardial contractility may include cardiac pacing, neurostimulation, or drug delivery. Additional details regarding detecting worsening myocardial contractility are provided in conjunction with FIG. 8 .
- Electrical-mechanical synchronization analysis is performed at block 410 and may include analysis of acoustical signals from heart valves for determining synchrony between EGM events and valve-related sounds, synchrony between valves in left and right heart chambers and/or upper and lower heart chambers, changes in valve sounds signifying regurgitation, or appearance of an S 3 -related sound. If poor synchrony between the left and right sides of the patient's heart is detected as determined at block 416 , a therapy response or alert is provided at block 420 .
- hydrophone signals are used for controlling cardiac resynchronization therapy (CRT) to improve cardiac chamber synchrony. Additional details relating to using hydrophone signals for detecting worsening synchrony and controlling CRT therapy are provided in conjunction with FIG. 7 .
- the analyses performed at blocks 406 , 408 and 410 for detecting various cardiac conditions may be performed on a continuous basis or in response to detecting a change in another signal, such as an EGM signal.
- the analyses may be implemented singly or in any combination in an IMD.
- FIG. 6 is a flow chart 500 of one method for using hydrophone signals for controlling shock therapy.
- an EGM signal is sensed from cardiac electrodes.
- the EGM signal (or an ECG signal) is a primary arrhythmia detection signal, monitored for initial detection of an arrhythmia. Initially, an arrhythmia is detected based on EGM signal monitoring, which may involve interval-based and/or morphology-based detection algorithms.
- EGM signal monitoring which may involve interval-based and/or morphology-based detection algorithms.
- hydrophones directed to receive signals specific to the mitral valve and the aortic valve are enabled at block 504 for providing acoustical signals to the IMD processing circuitry.
- hydrophone signals are received corresponding to the mitral valve and the aortic valve.
- the association between an event sensed on the EGM signal, such as an R-wave, and an event on the hydrophone signal is determined at block 506 .
- Detecting association would include a 1 : 1 correspondence of the EGM and hydrophone signal events and occurrence of the events within an expected time interval range. Accordingly, time intervals between an EGM signal event and a hydrophone signal event are measured at block 506 to determine if there is electrical-to-mechanical correlation between these events at decision block 510 . If not, the rhythm is detected as a shockable rhythm and cardioversion/defibrillation shock therapy is delivered at block 520 .
- Atrial EGM signals and valve-related sounds are measured at block 512 . If there is correlation between atrial electrical activity, e.g. a P-wave, and valve sounds, the rhythm is determined to be a supraventricular rhythm and a cardioversion/defibrillation shock is withheld at block 518 . If atrial EGM events are not associated with the aortic and mitral valve sounds at regular intervals, a ventricular arrhythmia is detected.
- the hydrophone signals are used to determine whether the ventricular arrhythmia is hemodynamically stable.
- the morphology of a hydrophone signal received from the direction of the aortic valve may be analyzed to determine if an expected signal morphology is present.
- the morphology analysis may include determining peak amplitudes and comparing the amplitude variability from beat-to-beat or comparing a peak amplitude to a threshold.
- Morphology analysis may include determining frequency content as sensed by multiple frequency range-specific transducers included in the hydrophone. If the frequency power spectrum changes significantly from an expected frequency power spectrum for normal sinus rhythm, hemodynamic instability may be detected. Baseline or threshold features of the hydrophone signals during normal sinus rhythm may be previously established and used for comparison at block 514 .
- High frequency signal components may provide blood flow information relating to changes in flow velocity, flow turbulence, valve regurgitation or other flow changes that an accelerometer or other acoustical sensors are insensitive to.
- Analysis of acoustical signals correlated to blood flow is not limited to signals arising from flow through a cardiac valve but may also include signals received by a hydrophone directed toward the aorta or other large artery or within a ventricular chamber.
- Time intervals between the mitral valve signal events and the aortic valve signal events may also be examined at block 514 . If stable acoustical signal morphology is found with no new sounds present, the ventricular tachycardia is detected as being hemodynamically stable. Shock therapy is withheld at block 518 .
- the process returns to block 501 and continues to acquire EGM and hydrophone signals until an arrhythmia is no longer detected or until the rhythm deteriorates to a hemodynamically unstable ventricular tachycardia as determined by the analyses performed at blocks 510 , 512 , and 514 . If the acoustical signal morphology, frequency content, or associated time intervals are found to be unstable or if new sounds are detected, the ventricular tachycardia is determined to be a shockable rhythm, and a shock therapy is delivered at block 520 .
- New sounds detected at block 514 may include sounds corresponding to S 3 or S 4 heart sounds.
- FIG. 7 is a flow chart 600 of a method for monitoring a heart failure condition using implantable hydrophones.
- Hydrophones carried by transvenous leads are positioned at targeted sensing locations at block 602 for directional sensing of specific arterial and cardiac sounds.
- Each hydrophone may include multiple transducers for sensitivity in individually specific frequency ranges.
- one hydrophone is directed toward the mitral valve in the LV and another one toward the tricuspid valve in the RV. Additional hydrophones may be directed toward the aorta or pulmonary artery or another large artery, the aortic valve, the pulmonic valve, along the LV, along the RV or other desired monitoring locations.
- the hydrophone signals are recorded on a periodic basis, e.g. hourly, daily, weekly, monthly or other interval selected by a clinician.
- the signals are analyzed to detect evidence of worsening HF or ventricular dyssynchrony.
- the amplitudes of the hydrophone signals are measured.
- Amplitude measurements may include determining a maximum or peak-to-peak amplitude from each transducer signal included in each hydrophone during a cardiac cycle or a portion thereof.
- the sound intensity in multiple frequency ranges is measured for each hydrophone, i.e. for each directional sensing location.
- the intensity of the mitral valve sounds in each of four frequency ranges and the intensity of the tricuspid valve sounds in each of four frequency ranges may be measured at block 606 from two hydrophones directed to preferentially receive mitral valve and tricuspid valve sounds, respectively.
- the number of frequency ranges monitored will depend on the number of transducers included in each hydrophone. All or a subset of available frequencies may be used for initial detection of a change in ventricular synchrony or HF status.
- time intervals between the left and right heart valve sounds are measured. For example, in a given frequency range, the time interval between a maximum signal peak in a mitral valve sound and a maximum signal peak in a tricuspid valve sound may be measured.
- the appearance of any new acoustical signal components is determined at block 610 .
- Occurrence of new sounds during time intervals not previously sensed may be an indication of a pathological change.
- the appearance of sounds occurring during ventricular diastole relating to the S 3 and S 4 heart sounds may indicate a deteriorating heart failure condition.
- Increased signal intensity during time intervals or in frequency ranges not associated with normal acoustical signal intensity may indicate valve regurgitation, dilation of the heart, ventricular dyssynchrony, changing blood pressure or flow patterns, or other conditions associated with worsening heart failure.
- the appearance of new acoustical signal components, i.e. increased intensity of the acoustical signal may be measured by measuring amplitudes or signal power for each of multiple frequency ranges and/or multiple time windows during the cardiac cycle.
- the measurements performed at block 606 , 608 and 610 are used to detect evidence of worsening heart failure (HF). If decreased amplitudes compared to baseline acoustical signals, dysynchrony in measured time intervals, or new acoustical signal components compared to baseline acoustical signals are detected, evidence of worsening heart failure is detected. If no evidence of worsening HF is detected, the process returns to block 604 to continue periodic monitoring of the acoustical signals.
- HF worsening heart failure
- time intervals between a fiducial point of the EGM sensed QRS signal and an acoustical event associated with mitral and/or tricuspid valve closure are measured and compared to a predefined optimal time interval range or baseline at block 616 .
- the time interval may be measured between an onset or peak of the QRS complex and an onset or peak of an S 1 sound, for example.
- the QRS-mitral valve (MV) time interval is outside an optimal time interval range, e.g. a threshold change from a previously established baseline measurement
- the AV interval used to control CRT is adjusted at block 618 .
- the AV interval may be adjusted until the QRS-MV time interval is within the optimal range, e.g. within a threshold range of the baseline measurement, or other optimization criteria may be used.
- An example of a threshold range that may be used is approximately ⁇ 20 ms.
- a time interval is measured between fiducial points of the acoustical signals received from the MV and from the tricuspid valve at block 620 . If the time interval is within a predefined range, e.g. within a threshold range such as within of a previously established baseline measurement, indicating synchrony of the left and right heart chambers as determined at block 620 , the process advances to block 624 . Otherwise, the inter-ventricular (VV) timing interval used to control CRT pacing pulses is adjusted at block 622 .
- VV inter-ventricular
- the VV interval may be adjusted until fiducial points, such as a peak amplitude, of the MV and tricuspid valve signals are synchronized in one embodiment though other optimization criteria may be used. If the fiducial points of the two valve signals are within approximately 20 ms, the ventricles may be considered synchronized in one example.
- the acoustical signals are examined for evidence of HF decompensation at block 624 .
- evidence of HF decompensation e.g., evidence of valve regurgitation, weakened (lower amplitude) or altered acoustical signal morphology, or presence of unexpected or abnormal acoustical signal components (in time or frequency domain)
- an alert may be generated at block 626 to notify the patient or clinician that medical attention may be warranted.
- a new therapy may be administered, which may involve neuromodulation using electrical stimulation or pharmacologic agents, or other automatic delivery of heart failure medication. The alert may notify the patient to take prescribed medications.
- FIG. 8 is a flow chart 700 of one method for detecting acute myocardial infarction (AM I) according to one embodiment.
- Acoustical signals detected by hydrophones having specific orientations for directional sensing of cardiac sounds are used in conjunction with EGM (or ECG) signal monitoring for evidence of myocardial ischemia.
- EGM or ECG
- S-T segment monitoring of the EGM signal is performed.
- S-T segment deviation is an indication of myocardial ischemia.
- Detection of S-T segment changes at block 702 may be performed as generally disclosed in U.S. Pat. No. 6,937,899 B2 (Sheldon, et al.), hereby incorporated herein by reference in its entirety.
- confirmation of AMI detection may be made at block 714 .
- the EGM signal analysis alone may not be conclusive.
- the S-T segment change may not reach a threshold change for a sustained period of time or the signal-to-noise ratio may preclude ischemia detection based on the EGM signal alone. If an S-T segment change is detected but EGM signal analysis is inconclusive in detecting AMI, one or more hydrophone signals are obtained at block 706 .
- one or more hydrophone signals are monitored at block 706 .
- Hydrophone signals are monitored for evidence of weakened contractility of the myocardium which may include altered flow patterns, valve regurgitation and increased intensity of diastolic sounds S 3 and S 4 .
- Valve regurgitation sounds sensed primarily from the mitral or tricuspid valves are an indication of weak ventricular contraction during ischemia which causes weakened valve closure or dyssynchronous closures.
- a hydrophone directed toward the mitral valve or aortic valve is used for sensing changes in valve sounds such as the appearance valve regurgitation, or changes in the amplitude, morphology or frequency content of mitral valve or aortic valve closure sounds. Since S 3 /S 4 occurs during relaxation of ventricles and may be caused by free ventricular free wall vibration, a hydrophone may be directed to the LV free wall for sensing S 3 - or S 4 -related sounds.
- an S-T segment change is transient without correlation to compromised contractility based on heart sounds, as determined at block 708 , the episode may be benign.
- the process may return to block 704 to continue to monitor for S-T segment deviation.
- measured changes in the hydrophone signal(s) may be compared to AMI detection thresholds at block 710 . If intensity, frequency or morphology changes in the hydrophone signal(s) reach an AMI detection threshold, and/or changes in hydrophone signals are correlated in time with S-T segment changes, AMI is detected at block 714 . Otherwise, the changes are attributed to myocardial ischemia at block 712 .
- EGM S-T segment deviation detected by an LV lead in conjunction with acoustical signal change associated with the mitral valve performance may indicate the ischemia/infarct location is in the LV free wall.
- EGM S-T segment deviation detected by an RV lead in conjunction with acoustical signal associated with tricuspid valve may indicate the ischemic/infarct location is in the RV.
- an alert and/or therapy response is provided. If AMI is detected at block 714 , an alert may be generated to notify the patient and clinician that immediate medical attention is warranted. A therapy may be adjusted, terminated or initiated in response to AMI detection. A therapy delivered in response to AMI detection may be a change to medication delivered by a drug pump, neuromodulation such as spinal cord stimulation for reducing sympathetic excitation, or a pacing therapy to reduce the heart rate. If myocardial ischemia is detected at block 712 , a patient and/or clinician alert may be generated at block 716 and an automated therapy may be delivered. Automatic therapies delivered in response to myocardial ischemia may include those listed above for responding to AMI.
- a therapy response may include termination of a therapy. For example, if a pacing therapy has been delivered, it may be terminated until medical attention is provided or ischemia is no longer detected.
- FIG. 9 is a flow chart 800 of a method for monitoring for hypertension using hydrophone signals.
- one hydrophone is directionally positioned for receiving arterial sounds from an artery such as the pulmonary artery, aorta, or carotid artery.
- the hydrophone will be placed transvenously with the hydrophone directed toward an artery for receiving a sound signal from an adjacent artery.
- a hydrophone may be positioned in the left innominate vein and directed to receive acoustical signals from the aorta.
- a second hydrophone may be directionally positioned for receiving signals from a cardiac valve such as the aortic valve or the pulmonic valve.
- a signal from the hydrophone directed to the aortic or pulmonic valve is monitored.
- a particular narrow band frequency may be selected for sensing from one of multiple transducers included in the hydrophone to obtain a signal associated with the closure of the valve with high specificity and sensitivity.
- the arterial sound is monitored at block 806 .
- the arterial signal may be monitored during aortic or pulmonic valve closure. If the intensity of the arterial sound signal increases during valve closure, an increase in blood pressure is detected at block 808 .
- hydrophone signal frequency components may be correlated to blood flow velocity through calibration techniques at the time of manufacture. For example using a blood flow loop, hydrophone signal frequency content may be calibrated for varying flow velocities and pressures.
- a therapy response to increased blood pressure may include neurostimulation to cause vasodilation or delivery of a vasodilator drug.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Physics & Mathematics (AREA)
- Acoustics & Sound (AREA)
- Pathology (AREA)
- Signal Processing (AREA)
- Vascular Medicine (AREA)
- Electrotherapy Devices (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Abstract
An implantable medical device system includes an elongated lead body carrying a hydrophone. In some embodiments, the elongated lead body has outer surface and an opening along the outer surface. The hydrophone is configured to receive acoustical signals through the opening of the lead body and generate an electrical signal representative of sounds produced at a targeted location along a patient's cardiovascular system. In some examples, the lead body outer surface has a shaped contour for directing the opening for receiving the sounds from a direction of the targeted location. A processor is enabled to receive signals from the hydrophone and detect a cardiac condition in response to the signals.
Description
- The present application claims priority and other benefits from U.S. Provisional Patent Application Ser. No. 61/639,234, filed Apr. 27, 2012, entitled “METHOD AND APPARATUS FOR CARDIAC FUNCTION MONITORING” (Attorney Docket P0033207.USP1), incorporated herein by reference in its entirety.
- The disclosure relates generally to medical devices and, in particular, to a heart sound recording apparatus and method for monitoring cardiac function.
- Heart sounds contain a great deal of diagnostic information. A stethoscope is a standard instrument used in clinical examinations and has aided in enabling clinicians to become familiar with normal and abnormal heart and lung sounds. Clinicians typically refer to four heart sounds, S1, S2, S3 and S4. The first heart sound, S1, corresponds to the start of ventricular systole and is generated by the abrupt closure of the mitral and tricuspid valves between the ventricles and atria as ventricular pressure exceeds atrial pressure. The second heart sound, S2, is generated by the closure of the aortic and pulmonary valves, near the end of ventricular systole and start of ventricular diastole.
- The third heart sound, S3, is associated with early, passive diastolic filling of the ventricles, and the fourth heart sound, S4, is associated with late, active filling of the ventricles due to atrial contraction. The third sound is generally difficult to hear in a normal patient using a stethoscope, and the fourth sound is generally not heard in a normal patient. Presence of the third and fourth heart sounds may indicate a pathological condition.
- Implementation of acoustical sensors in implantable medical devices such as cardiac pacemakers has been proposed because of the valuable information that can be obtained relating to the occurrence of the standard heart sounds S1, S2, S3 and S4 (if present). In addition to the standard S1 through S4 heart sounds, a large amount of acoustical information correlated to blood flow through the heart chambers, valves and arteries could potentially be gleaned from an implantable acoustical sensor. However, even when implanted, an acoustical sensor positioned to sense cardiac sounds will be subjected to lung and other physiological sounds and non-physiological noise. For example, heart sound sensing using a piezoelectric transducer positioned in the pacemaker housing will be somewhat hampered due to filtering of high frequency cardiac sounds by the lungs and the influence of respiration on the acoustical signal. A need remains, therefore, for an implantable acoustical sensor useful for monitoring cardiac sounds with high specificity and sensitivity.
-
FIG. 1 is a functional block diagram of an IMD system for acquiring acoustical signals for monitoring cardiac function. -
FIG. 2 is a functional block diagram of the IMD shown inFIG. 1 . -
FIG. 3A is a view of a distal portion of an acoustical sensing lead incorporating a hydrophone according to one embodiment. -
FIG. 3B is an enlarged sectional view of another example of a lead carrying a hydrophone for sensing cardiac and blood-flow related signals. -
FIG. 3C is an enlarged sectional view of a distal tip of a lead carrying a hydrophone according to another embodiment. -
FIG. 4A is a schematic view of an acoustical sensing lead carrying multiple hydrophones according to one embodiment. -
FIG. 4B is a schematic illustration of a lead carrying hydrophones for directional sensing of cardiac and blood flow related sounds. -
FIG. 4C is a cut-away view of a patient heart depicting an RV lead carrying hydrophones for directional sensing of heart and blood flow sounds. -
FIG. 5 is a flow chart of a method for monitoring cardiac function using an implantable medical device system including hydrophones. -
FIG. 6 is a flow chart of one method for using hydrophone signals for controlling shock therapy. -
FIG. 7 is a flow chart of a method for monitoring heart failure using implantable hydrophones. -
FIG. 8 is a flow chart of one method for detecting acute myocardial infarction (AMI) according to one embodiment. -
FIG. 9 is a flow chart of a method for monitoring for hypertension using hydrophone signals. - In the following description, references are made to illustrative embodiments. It is understood that other embodiments may be utilized without departing from the scope of the disclosure. As used herein, the term “module” refers to an application specific integrated circuit (ASIC), an electronic circuit, a processor (shared, dedicated, or group) and memory that execute one or more software or firmware programs, a combinational logic circuit, or other suitable components that provide the described functionality.
-
FIG. 1 is a functional block diagram of anIMD system 100 for acquiring acoustical signals for monitoring cardiac function.System 100 includesIMD 10 coupled to leads 118, 120, and 122 which carry multiple electrodes for sensing cardiac EGM signals and/or delivering cardiac pacing pulses.IMD 10 is configured for bidirectional communication withprogrammer 170.IMD 10 may be, for example, an implantable pacemaker, cardiovertor, and/or defibrillator that provides electrical signals toheart 112 via electrodes coupled to one or more ofleads - Each of
leads hydrophone hydrophones - The
hydrophones - The opening may extend along the shaped contour, i.e. along a pre-shaped curve, and/or along a recessed surface or along a convex surface. The opening may alternatively extend along the outer surface of the lead body proximally or distally to a pre-shaped curve for directing the opening toward a targeted cardiovascular location for receiving sounds generated at the targeted location. The lead body opening and associated hydrophone receiving sound signals through the opening may be positioned along an outer side surface of the lead body as generally shown in
FIG. 1 . Alternatively or additionally, an opening and associated hydrophone may be positioned along an outer surface of the distal tip of the lead body. - The hydrophone and the lead body may be hermetically sealed to prevent influx of body fluids into the lead body and into the hydrophone. Various embodiments of a lead carrying a hydrophone and having an outer surface including a shaped contour for directing an opening toward a targeted sound source to enable directional sensing of cardiovascular sounds by a hydrophone will be further described in detail in conjunction with
FIGS. 3A through 4C . -
IMD 10 is shown configured for multi-chamber pacing and sensing in the right atrium (RA) 126, the right ventricle (RV) 128, and the left ventricle (LV) 132 usingleads patient 114 according to one embodiment.IMD 10 may additionally or alternatively be configured for detecting cardiac arrhythmias and delivering arrhythmia therapies, such as anti-tachycardia pacing therapy and cardioversion/defibrillation shocks.IMD 10 is one example of numerous types of devices that an acoustical signal sensing system and associated methods for monitoring cardiac conditions as described herein may be implemented. Such devices may be capable of delivering a therapy including one or more of cardiac pacing, neurostimulation, or fluid delivery for administering a pharmacological agent or biological fluid. - In other embodiments, an IMD system including acoustical signal monitoring may be provided as a monitoring-only system which acquires and analyzes acoustical signals for diagnostic and prognostic purposes without having therapy delivery capabilities. Furthermore, a device for performing the methods described herein is not limited to fully implantable medical devices but may be implemented using external components coupled to implantable leads or catheters carrying at least one hydrophone positioned in the blood stream and thus may include a combination of implantable and external components. As such, the
system 100 shown inFIG. 1 is one illustrative embodiment of a system in which a hydrophone and associated methods described herein may be implemented. -
IMD 10 delivers RV pacing pulses and senses RV intracardiac EGM signals usingRV tip electrode 140 andring electrode 142 positioned in theRV 128.RV lead 118 is shown to carry acoil electrode 162 which may be used for delivering high voltage cardioversion or defibrillation shock pulses.IMD 10 senses LV EGM signals and delivers LV pacing pulses using theelectrodes 144 carried by a multipolarcoronary sinus lead 120, extending through the right atrium (RA) 126 and into acardiac vein 130 via the coronary sinus. In some embodiments,coronary sinus lead 120 may include electrodes positioned along the left atrium (LA) 136 for sensing left atrial EGM signals and deliver LA pacing pulses. -
IMD 10 senses RA EGM signals and delivers RA pacing pulses usingRA lead 122, carryingtip electrode 148 andring electrode 150.RA lead 122 is shown carrying acoil electrode 166 which may be positioned along the superior vena cava (SVC) for use in delivering cardioversion/defibrillation shocks. In other embodiments, RV lead 118 carries both theRV coil electrode 162 and theSVC coil electrode 166. WhileIMD 10 is shown in a right pectoral implant position inFIG. 1 , a more typical implant position, particularly whenIMD 10 is embodied as an ICD, may be a left pectoral implant position. -
IMD 10 includes internal circuitry for performing the functions attributed toIMD 10 and a housing 160 encloses the internal circuitry. It is recognized that the housing 160 or portions thereof may be configured as an active electrode for use in cardioversion/defibrillation shock delivery or used as an indifferent electrode for unipolar pacing or sensing configurations.IMD 10 includes aconnector block 134 having connector bores for receiving proximal lead connectors ofleads leads connector block 134. -
IMD 10 may provide acoustical signal data toprogrammer 170 via wireless telemetry. Acoustical signal data and/or an alarm or alert relating to a detected cardiac condition may be transmitted toprogrammer 170 for display or further transmission to a user via a communication network. Acoustical signal monitoring procedures may be performed automatically byIMD 10 according to a monitoring protocol or upon a userrequest using programmer 170. A patient or physician alert and/or therapy adjustments may be made automatically byIMD 10 in response to acoustical signal analysis. Alternatively, acoustical signals may be obtained byIMD 10 and transmitted toprogrammer 170 for analysis and display of results to a user. -
Programmer 170 includes a display 172, aprocessor 174, auser interface 176, and acommunication module 178 including wireless telemetry circuitry for communication withIMD 10. In some examples,programmer 170 may be a handheld device or a microprocessor based home monitor or clinical programming device. A user, such as a physician, technician, nurse or other clinician, may interact withprogrammer 170 to communicate withIMD 10. For example, the user may interact withprogrammer 170 viauser interface 176 to retrieve physiological or diagnostic information fromIMD 10. A user may also interact withprogrammer 170 toprogram IMD 10, e.g., select values for operational parameters of the IMD. A user interacting withprogrammer 170 may requestIMD 10 to perform an acoustical signal analysis algorithm or request data stored byIMD 10 relating to acoustical signals.Processor 174 receives data fromIMD 10 for use in generating a display presented on display 172 including information relating to acoustical data and any notifications or alert messages. -
Programmer 170 includes acommunication module 178 to enable wireless communication withIMD 10. Examples of communication techniques used bysystem 100 include low frequency or radiofrequency (RF) telemetry, which may be an RF link established via Bluetooth, WiFi, or MICS. In some examples,programmer 170 may include a programming head that is placed proximate theIMD 10 to establish and maintain a communication link, and inother examples programmer 170 andIMD 10 may be configured to communicate using a distance telemetry algorithm and circuitry that does not require the use of a programming head and does not require user intervention to maintain a communication link. - It is contemplated that
programmer 170 may be coupled to a communications network viacommunications module 178 for transferring data to a remote database or computer to allow remote management of thepatient 114 using the acoustical signal monitoring described herein. Remote patient management systems may be configured to utilize the presently disclosed techniques to enable a clinician to review data derived from acoustical signals and authorize programming of IMD control parameters. For example, acoustical signals or parameters derived from the signals may be transferred fromprogrammer 170 to a clinic or other expert center for review. The clinician or other expert may then authorize programming of the IMD for delivering or adjusting a therapy via a communications network andprogrammer 170. Reference is made to commonly-assigned U.S. Pat. No. 6,599,250 (Webb et al.), U.S. Pat. No. 6,442,433 (Linberg et al.), U.S. Pat. No. 6,418,346 (Nelson et al.), and U.S. Pat. No. 6,480,745 (Nelson et al.) for general descriptions and examples of network communication systems for use with implantable medical devices for remote patient monitoring and device programming. -
FIG. 2 is a functional block diagram ofIMD 10 shown inFIG. 1 .IMD 10 includes anacoustical sensing module 12 coupled to one or moreacoustical sensors 11, cardiac EGMsignal sensing circuitry 14 andtherapy delivery module 15 both coupled toelectrodes 13,control processor 16 and associatedmemory 18, andtelemetry circuitry 20.Acoustical sensing module 12 receives signals fromacoustical sensors 11 for sensing acoustical signals which are provided to controlprocessor 16. -
Acoustical sensing module 12 is configured to receive signals fromsensors 11 embodied as hydrophones for sensing acoustical signals from one or more targeted locations in the heart or blood vessels. For example,acoustical sensing module 12 may include multiple “channels” configured to particularly sense specific cardiac sounds based on sensing location and/or frequency.EGM sensing circuitry 14 may be used bycontrol processor 16 to set sensing windows used byacoustical sensing module 12 for sensing acoustical signals during the cardiac cycle.Acoustical sensing module 12 may include one or more sense amplifiers, filters and rectifiers for optimizing a signal-to-noise ratio and obtaining acoustical signals useful for deriving parameters used for monitoring cardiovascular function. Separate and unique amplification and filtering properties may be provided for sensing different acoustical signal channels to improve signal quality as needed. -
Acoustical sensors 11 are implemented as hydrophones which are positioned transvenously, within a vein, artery or heart chamber and may correspond to thesensors FIG. 1 , or any other hydrophones shown herein. In various embodiments, one or more leads positioned in a patient's blood stream may carry one or more sensors as will be further described herein. - When multiple acoustical sensors are implemented in an IMD system, switching
circuitry 26 may be used to control which acoustical sensors, or which transducers within a sensor, are coupled tosensing module 12. An electrical signal produced by the sensor(s) representative of sounds or vibrations produced by the heart or blood is processed, which may include digital conversion, to derive acoustical signal parameters, such as amplitude content, frequency content, relative time intervals, or the like as derived byacoustical sensing module 12 and/orcontrol processor 16. -
EGM sensing circuitry 14, coupled to at least one sensing electrode pair included inelectrodes 13, is provided to sense cardiac signals, e.g. P-wave and/or R-wave signals attendant to the depolarization of the atria and ventricles of the heart, respectfully.EGM sensing circuitry 14 is coupled toelectrodes 13, which may include transvenous intracardiac electrodes or epicardial electrodes for sensing cardiac EGM signals. In alternative embodiments, cardiac electrical signals may be sensed using subcutaneous or submuscular electrodes for sensing ECG signals. ECG signals and EGM signals are referred to herein generally as “cardiac electrical signals”.Electrodes 13 may correspond to theelectrodes FIG. 1 but may include fewer or more electrodes positioned in operative relation to one or more heart chambers. Cardiac electrical signals may be used for timing sensing windows used byacoustical sensing module 12 for obtaining acoustical signals. Cardiac electrical signals may additionally or alternatively be used bycontrol processor 16 for timing therapy delivery, such as electrical stimulation pulses during CRT or other pacing therapy, e.g. according to programmed pacing intervals, such as a programmed atrial-ventricular (AV) interval and/or inter-ventricular (VV) interval. -
Therapy delivery module 15 is provided for delivering pacing pulses to the patient's heart viaelectrodes 13 using programmable pacing parameters.Electrodes 13 used for delivering pacing pulses may include dedicated pacing electrodes, or may include shared pacing and sensing electrodes. Switching circuitry may be included intherapy delivery module 15 andsensing module 14 for selecting whichelectrodes 13 are coupled toEGM sensing circuitry 14 and which electrodes are coupled totherapy delivery module 15 as well as the polarity of such electrodes. While two electrodes are shown coupled totherapy delivery module 15 and two electrodes are shown coupled toEGM sensing module 14 inFIG. 2 , it is recognized that multiple sensing and pacing channels corresponding to multiple heart chambers may require multiple electrodes coupled to each ofsensing module 14 andtherapy delivery module 15 and such connections may be controlled by a switching circuit. -
Therapy delivery module 15 is controlled bycontrol processor 16 to deliver pacing pulses according to a therapy delivery algorithm.Control processor 16 receives signals fromEGM sensing circuitry 14 for use in controllingtherapy delivery module 15 to deliver appropriately timed pacing pulses and/or cardioversion/defibrillation shock pulses. In other embodiments, neurostimulation may be delivered. In still other embodiments, therapy delivery module may include a fluid pump for delivering a drug for treating a detected condition. As will be described herein, an automatically delivered therapy may be started, stopped or adjusted bycontrol processor 16 in response to parameters derived from acoustical signals. -
Control processor 16 may include any one or more of a microprocessor, a digital state machine, a digital signal processor (DSP), an application specific integrated circuit (ASIC), a field-programmable gate array (FPGA), or equivalent discrete or integrated logic circuitry. In some examples,processor 16 may include multiple components, such as any combination of one or more microprocessors, one or more controllers, one or more DSPs, one or more ASICs, or one or more FPGAs, as well as other discrete or integrated logic circuitry. The functions attributed to controlprocessor 16 herein may be embodied as software, firmware, hardware or any combination thereof, implemented in a single device or distributed across two or more devices, which may include one or more implantable devices, external devices, or a combination of both. -
Control processor 16 includes an acousticalsignal analysis module 22 for analyzing acoustical signals obtained by sensingmodule 12. Theanalysis module 22 includes circuitry and/or computer-readable instructions for performing an algorithm for deriving parameters and/or trends or relative changes in parameters derived from the acoustical signals. -
Memory 18 stores algorithms used bycontrol processor 16 for performing monitoring procedures. Such algorithms may include monitoring protocols for acquiring acoustical signals as well as controlling therapy response and/or triggering patient or clinician alert generation.Memory 18 may also be used to store other data and information used bycontrol processor 16 for controlling device functions, including a pacing or neurostimulation therapy delivered bytherapy delivery module 15, controlling sensing functions byEGM sensing circuitry 14, controllingtelemetry module 20, and controllingpatient alert 24 in response to detecting an alert condition based on acoustical signals and cardiac electrical signals. Alerts or notifications may be triggered bycontrol processor 16 in response to acoustical signal measurements and transmitted to an external programmer viatelemetry 20. Alternatively or additionally, apatient alert module 24 may generate audible sounds, a vibration, electrical stimulation to cause muscle twitching, or other alert signal perceivable by the patient. -
Memory 18 may include computer-readable instructions that, when executed byprocessor 16,cause IMD 10 andprocessor 16 to perform various functions attributed throughout this disclosure toIMD 10 andprocessor 16. The computer-readable instructions may be encoded withinmemory 18.Memory 18 may comprise computer-readable storage media including any volatile, non-volatile, magnetic, optical, or electrical media, such as a random access memory (RAM), read-only memory (ROM), non-volatile RAM (NVRAM), electrically-erasable programmable ROM (EEPROM), flash memory, or any other digital media with the sole exception being a transitory, propagating signal. - It is contemplated that
IMD 10 may include or be coupled toother sensors 28 which provide signals to controlprocessor 16 correlated to other physiological conditions of the patient.Sensors 28 may include an activity sensor, posture sensor, pressure sensor, oxygen sensor, temperature sensor, impedance sensor or the like. Sensor signals may be used bycontrol processor 16 in detecting a physiological condition of the patient indicating a need to provide or adjust therapy or generate a patient alert. -
Telemetry module 20 is configured for bidirectional communication with anexternal programmer 170 or computer operating software for programming theIMD 10.Control processor 16 may generate acoustical data and information relating to a monitored condition that is transmitted to an external device viatelemetry module 20 for review by a clinician. In some embodiments, functions attributed herein to controlprocessor 16 may be performed across one or more processors that may include an external processor receiving data fromtelemetry module 20, such asprocessor 174 ofexternal programmer 170. -
FIG. 3A is a view of a distal portion of anacoustical sensing lead 200 incorporating a hydrophone according to one embodiment.Lead 200 includes an elongatedlead body 202 having a curve or bend 204 imposing a substantially “J”-shaped distal portion of thelead body 202. A pre-formed shape or curve oflead body 202 can provide a desired directionality of a hydrophone for “listening” to targeted cardiac sounds or blood flow at particular cardiovascular locations. For example, lead 200 is shown including twohydrophones Hydrophone 210 is positioned at the distallead end 206 which can be positioned for receiving sounds from a particular direction corresponding to sound source A due to the J-shape. - A
second hydrophone 220 may be positioned along an outer diameter of acurve 220 to enablehydrophone 220 to receive sounds primarily from a different direction(s) thanhydrophone 210. Thehydrophones -
Hydrophone 210 includes a hermetically-sealedhousing 216. A thin diaphragm ormembrane 214 extends along an exposed portion ofhousing 216 and an array ofacoustical transducers 212 are positioned along thediaphragm 214 within thehousing 216. The exposed portion ofhousing 216 may be substantially flat or having a concave, conical or spherical surface to facilitate directional sensing of acoustical signals. Thehousing 216 may include a radio-opaque material such that the direction that thesensor 210 is facing relative to a patient's cardiovascular anatomy may be determined under fluoroscopy or x-ray. - Similarly,
sensor 220 includes ahousing 226 mounted withinlead body 202 and enclosingacoustical transducers membrane 224 extends over acoustical transducers 222, such that transducers 222 are hermetically sealed withinlead body 202.Sensor 220 is shown to include areference mark 228 which may be provided as radio-opaque material alonghousing 226 for indicating the directionality ofsensor 220 during an implantation or re-positioning procedure. -
Acoustic transducer arrays 212 and 222 are embodied as piezoceramic transducers in one embodiment. Thearrays 212 and 222 include two or more transducers of different sizes or other differing properties for providing sensitivity at different selected frequencies. The piezoceramic transducers may range from one to several millimeters in size to obtain signals responsive to a narrow band of frequencies from an overall range of sound frequencies from 10 Hz to 10 kHz. Alongdiaphragm 214, piezoceramic materials (or films) each having different frequency responses can be packed parallel to sense different sound frequencies. For example, individual transducers may be built to have different frequency ranges of 10-100 Hz, 100-1000 Hz, 1000-10 KHz and so on. - In alternative embodiments, the acoustic transducers may include a membrane capsule transducer or iridium tin oxide (ITO). Individual ITO transducers included in an array of transducers may range from tens of micrometers to one millimeter in width with a thickness of 100 nm to 1000 nm for obtaining different sound frequencies. The
transducer arrays 212 is depicted in a linear arrangement inFIG. 3A , but may alternatively be arranged circumferentially or in other patterns relative to one another. - By placing multiple transducers responsive to different resonant frequencies within a hydrophone, different aspects of blood flow, blood pressure, and cardiac function such as wall motion and relaxation or valve closure and opening, may be monitored using sounds received from a targeted direction and in a targeted frequency range. For example, different frequency components of sound due to valve opening and closure may be examined to detect a change in blood pressure or cardiac function. Changes in power of the acoustical signal in different frequency ranges may be indicative of a change in blood flow pattern due to a change in a cardiac condition.
- One or more piezoelectric transducers included in an acoustical sensor may be positioned within the sensor with its piezoelectric axis aligned in parallel with a direction of targeted sound source. In one embodiment, each of the
transducers 212 is arranged with its piezoelectric axis aligned with or parallel to a direction of targeted sound source A, as indicated by the arrows extending throughtransducers 212. Thetransducers 212 will be less sensitive or insensitive to sounds arriving from directions that are not parallel to the aligned piezoelectric axes of thetransducers 212. - In alternative embodiments, as shown by way of example in
sensor 220, multiple transducers may be positioned within the sensor with associated piezoelectric axes aligned in different directions.Transducer 222 a is positioned with its piezoelectric axis oriented in a first direction, as indicated by the arrow extending throughtransducer 222 a, andtransducer 222 b is positioned with its piezoelectric axis oriented in a second direction, as indicated by the arrow extending throughtransducer 222 b, that is different than the first direction.Transducer 222 a is positioned with its piezoelectric axis oriented in a direction that is substantially parallel to the direction of targeted soundsource B. Transducer 222 b is positioned with its associated piezoelectric axis substantially parallel to the direction of a different targeted sound source C. A given piezoelectric transducer will be less sensitive or insensitive to sounds arriving from a source that is in a direction from the transducer that is substantially orthogonal to the piezoelectric axis. As such, directional sensitivity of an acoustical sensor includes a selected orientation of a piezoelectric axis of one or more transducers in some embodiments. -
FIG. 3B is an enlarged sectional view of another example of a lead 250 carrying a hydrophone for sensing cardiac and blood-flow related signals.Lead 250 includes an elongatedlead body 251 having anouter side 252. Ahydrophone 260, which may includemultiple transducers 262 responsive to distinct frequency ranges, is fixed along anopening 253 along anouter side 252 of thelead body 251. Theopening 254 is shown formed along a recessedsurface 254 ofouter side 252, extending between aside wall 256. A raisedflange 258 may surround the recessedsurface 254, raising the height ofside wall 256. Theouter surface 263 ofhydrophone 260 is hermetically sealed by a thin, biocompatible membrane or coating. In various embodiments, a thin film or coating of polyurethane, polytetrafluoroethylene (PTFE), silicone medical adhesive, or other blood compatible coatings or layers, which may include a bioactive layer or a layer that promotes cellular overgrowth, such as endothelial cell overgrowth may be applied overouter surface 263. -
Transducers 262 are mounted along ahybrid circuit board 264 or other substrate which enables fixation ofhydrophone 260 alonglead body 251 and electrical connection toindividual conductors 266 electrically coupled to each oftransducers 262.Hybrid circuit board 264 and/orconductors 266 may include filters andamplifiers 268 for filtering and amplification of each transducer signal according to distinct filtering and amplification properties selected for each distinct frequency range of theindividual transducers 262. -
FIG. 3C is an enlarged sectional view of a distal tip of a lead 270 according to another embodiment.Lead body 271 terminates at adistal tip 272 that is substantially spherical in shape, i.e.tip 272 is rounded forming a portion of a sphere. Anopening 273 formed in thespherical tip 272 exposes one ormore transducers 282 included inhydrophone 280. The exposed outer surface ofhydrophone 280 is hermetically sealed alonglead tip 272 by a coating or thin layer of a biocompatible material such as polyurethane or silicone as described above. As will be further described below, positioning a hydrophone along a recessed surface (as shown inFIG. 3B ) or a rounded, conical or spherical surface of a lead body can provide greater directional sensitivity of the hydrophone. - The
transducers 282 are mounted on asubstrate 284, which may be a hybrid circuit board, which enableshydrophone 280 to be fixedly coupled withinlead body 271 atdistal tip 272.Transducers 282 are electrically coupled toindividual conductors 286 viasubstrate 284 for carrying each transducer signal back to theacoustic sensing module 12 of the associated IMD. Eachtransducer 282 may be provided with unique filtering andamplification 288. -
FIG. 4A is a schematic view of anacoustical sensing lead 300 according to one embodiment.Lead 300 includes an elongatedlead body 302 carryingmultiple hydrophones 304A through 304D. Each hydrophone may include one or more transducers to provide acoustical sensitivity in multiple frequency ranges. Eachhydrophone 304A-304D may be positioned for sensing acoustical signals from a particular direction at different anatomical locations. For example,hydrophones 304A-304D may be spaced alonglead body 302 such that whenlead 300 is deployed along a blood vessel or the heart, eachhydrophone 304A-304D is positioned at a particular level and location along a heart chamber or blood vessel to receive sounds from a targeted location. - In one embodiment, lead 300 is provided as a coronary sinus lead adapted for advancement through the coronary sinus and along a cardiac vein for positioning
hydrophones 304A-304D at different locations along the patient's heart.Hydrophones 304A-304D can be positioned at different levels along the heart, e.g. along the left atrium, the mitral valve, the aortic valve, or the left lateral free wall along a mid-portion of the left ventricle. By providing multiple hydrophones having directional sensitivity, each having multiple transducers for specific sensitivity in multiple frequency ranges, a large amount of acoustical data specific to particular locations and blood flow phenomenon or cardiac motion can be obtained for monitoring cardiac function. - Openings along
lead body 302 through which hydrophones 304A-304D receive sound waves may be defined in different directions for each ofhydrophones 304A-304D to provide directional sensitivity of each hydrophone. For example, one hydrophone may be directed toward the aortic valve and one hydrophone may be directed toward the mitral valve. In one embodiment, a J-shaped lead as shown inFIG. 3 may be positioned in the right ventricle to direct a hydrophone for receiving signals from the direction of the mitral valve and a coronary sinus lead having multiple hydrophones may be positioned along a cardiac vein to direct at least one hydrophone in the direction of the aortic valve. In another embodiment, a lead in the right ventricle may carry a hydrophone directed toward the pulmonary valve and a coronary sinus lead may carry a hydrophone directed toward the aortic valve. Collection of directionally sensitive acoustical signals allows changes in opening and closing times between the two valves to be closely monitored. - A lead carrying a hydrophone may additionally carry other sensors or electrodes allowing multiple physiological signals to be acquired using the same lead. For example, a lead may carry electrodes for sensing cardiac EGM signals in addition to sensing acoustical signals to enable analysis of correlation between electrical cardiac activity and mechanical cardiac activity.
-
FIG. 4B is a schematic illustration of a lead 350 carrying hydrophones for directional sensing of cardiac and blood flow related sounds.Lead 350 is shown carrying twohydrophone sensors Lead 350 includes an elongatedlead body 352 having adistal end 354 andouter side 356.Outer side 356 includes a recessedsurface 360 surrounded by asidewall 362.Sidewall 362 may extend in a generally circular, oval or rectangular shape around recessedsurface 360. Recessedsurface 360 andsidewall 362 promote directional sensitivity ofhydrophone 368. Recessedsurface 360 is shown to be concave inFIG. 4B , but may be substantially flat or convex in other embodiments. -
Sidewall 362 extends fromouter surface 356 to recessedsurface 360.Lead body 350 may further include a raised lip, rim, orflange 366 along an edge ofsidewall 362 definingopening 364. The protrudingflange 366 extendssidewall 362 radially outward fromouter side 356 and deflects sound waves not in approximate alignment with recessedsurface 360.Sidewall 362 is shown to be substantially vertical, i.e. perpendicular toouter side 356. In other embodiments sidewall 362 may be angled with respect toouter side 356 andsurface 360. -
Hydrophone 368 will be more sensitive to sound waves generated by a source at location B than at A or C due to the recessed,concave surface 360 along which hydrophone 368 is mounted. Sound waves traveling directly from sources A and C towardlead body 352 will be reflected or obstructed byflange 366. Sound orvibrations reaching hydrophone 368 from sources not in approximate alignment withopening 364 and recessedsurface 360 will be substantially diminished compared to a configuration in which hydrophone 368 is positioned along a non-recessed portion ofouter side 356. In this way, a recessedsurface 360 andsidewall 362 formed along anouter side 356 oflead body 350 promotes greater sensitivity of sounds produced by specific structures or at specific locations in the heart or blood vessels. In other examples,lead body 352 may be formed with multiple recessed surfaces formed at different radial and longitudinal locations alongouter side 356 to hold hydrophones for receiving sounds from different preferential directions. -
Hydrophone 378 is shown positioned at distallead end 354 along a substantially flat recessedsurface 370.Sidewall 372 defines aconical opening 374 through which hydrophone receives sounds from a preferential direction D. Sounds arriving from sources A, B and C will be deflected away fromhydrophone 378. In this case,sidewall 372 is shown angled with respect to a substantially flat recessedsurface 370. It is contemplated that in other embodiments, a hydrophone positioned at a distal lead end may be positioned along a concave or convex recessed surface extending between a substantially perpendicular or angled surrounding sidewall. -
FIG. 4C is a cut-away view of a patient heart depicting anRV lead 320 carrying hydrophones for directional sensing of heart and blood flow sounds.Lead 320 is a substantially J-shaped lead carrying aproximal hydrophone 322, a moredistal hydrophone 324, and adistal tip hydrophone 326.Proximal hydrophone 322 and moredistal hydrophone 324 are positioned along the outer side of thelead body 332, for example in a manner similar tosensor 368 shown inFIG. 4B .Distal tip hydrophone 326 is located in the distal tip oflead 320, for example in a manner similar tosensor 378 shown inFIG. 4B . -
Proximal hydrophone 322 is located along an outer side of thelead body 332 such that it is positioned at the level of the superior vena cava (SVC) when thedistal tip 330 is fully advanced into the RV. Positioned in the SVC,proximal hydrophone 322 can be directed toward theaorta 340 for receiving blood flow sounds in the aorta. As will be described below, blood flow sounds in the aorta may be analyzed to detect changes in blood flow velocity for use in detecting a cardiac condition. In alternative embodiments, a hydrophone may be positioned along the innominate vein for sensing blood flow sounds in the adjacent aorta. -
Distal hydrophone 324 is positioned along the outer side of thelead body 332 such that it can be directed toward the pulmonary valve (PV) 342 when the leaddistal tip 330 is fully advanced into the RV.Hydrophone 324 is positioned along the outer side corresponding to the inside curve of the “J” shaped bend oflead 320.Hydrophone 324 can be positioned to generate a signal with preferential sensitivity to pulmonary valve sounds and thereby generate a signal highly correlated to sounds produced by pulmonary valve opening and closure. When configured along a recessed surface oflead body 332 as described above, with or without a surrounding protruding flange,hydrophone 324 will be less sensitive to sounds or vibrations arriving from other structures such as thetricuspid valve 344. -
Distal tip hydrophone 326 is located at thetip 330 of the J-shaped distal end oflead 320 such that it faces back toward thetricuspid valve 344 through which thelead 320 is advanced into the RV from the RA. Being within a recess oflead tip 330 surrounded by a sidewall as described in conjunction withFIG. 4 b,hydrophone 326 will be preferentially sensitive to sounds produced by the opening and closure of thetricuspid valve 344 and less sensitive to sounds produced by other structures, such as thepulmonary valve 342. - This illustrative embodiment provides three hydrophones carried by a single lead body configured to preferentially sense acoustical signals from three different target sources, the aorta, the pulmonary valve and the tricuspid valve. It is recognized that numerous configurations and variations exist for deploying one or more hydrophones to particular locations, carried by one or more leads and each directed toward a preferential source of sound or vibration associated with cardiac function and blood flow.
- It is recognized that
lead 320 may be provided with one or more fixation members alonglead body 320 to anchor the lead body at a desired location and to maintain a desired position and directional orientation ofhydrophones FIG. 4C , a helical screw, hook or tine may be located along the curve of the J-shaped portion of the lead, at a distal end of the lead, or at proximal locations for anchoring the lead and respective hydrophones at desired locations. -
FIG. 5 is aflow chart 400 of a method for monitoring cardiac function using an implantable medical device system including hydrophones.Flow chart 400 is intended to illustrate the functional operation of the device, and should not be construed as reflective of a specific form of software or hardware necessary to practice the methods described. It is believed that the particular form of software, firmware and hardware will be determined primarily by the particular system architecture employed in the device and by the particular detection and therapy delivery methodologies employed by the device. Providing software to accomplish the described functionality in the context of any modern IMD, given the disclosure herein, is within the abilities of one of skill in the art. - Methods described in conjunction with flow charts presented herein may be implemented in a non-transitory computer-readable medium that includes instructions for causing a programmable processor to carry out the methods described. A “non-transitory computer-readable medium” includes but is not limited to any volatile or non-volatile media, such as a RAM, ROM, CD-ROM, NVRAM, EEPROM, flash memory, or other computer-readable media, with the sole exception being a transitory, propagating signal. The instructions may be implemented as one or more software modules, which may be executed by themselves or in combination with other software.
- At
block 402, multiple implantable hydrophones are implanted at desired locations for targeted acoustical sensing. In one embodiment, hydrophones are positioned for sensing mitral valve sounds, aortic valve sounds, tricuspid valve sounds, pulmonary valve sounds, LV free wall motion, and blood flow in the aorta or another major artery. - At
block 404, acoustical signals from the positioned hydrophones are recorded. Atblocks 406 through 410, analyses of the acoustical signals are performed to detect various cardiac conditions. Atblock 406, rhythm stability analysis is performed. Rhythm stability analysis is performed to detect a shockable rhythm atblock 412. As further described below, rhythm stability analysis may include analysis of synchrony between electrical events and mechanical events and/or between mechanical events identified using signals received from the hydrophones. - A shockable rhythm is detected at
block 412 based on fast electrical events and a low correlation between electrical and mechanical events or other changes in the hydrophone signals.Processor 16 makes a therapy decision and/or generates an alert atblock 420. A cardioversion/defibrillation shock therapy may be delivered atblock 420 in response to detecting a shockable rhythm based on signals received from the hydrophone(s). Additional details regarding using hydrophone signals for controlling a shock therapy are presented in conjunction withFIG. 6 . - Contractility analysis is performed at
block 408. Analysis to detect changes in myocardial contractility may include measuring the power and frequency content of a hydrophone signal(s) directed toward the pulmonary and/or aortic valves or mitral and tricuspid valves, the appearance of S3-related sounds, or changes in blood flow as detected by an increase in frequency components correlated to slow blood flow. As an example, a hydrophone may be advanced transvenously and placed directionally toward an artery extending adjacent to the vein. As described above, a hydrophone positioned in the superior vena cava or the innominate vein may be directed for preferential sensing of blood flow sounds in the aorta. The sound or vibration caused by blood flow in the artery is then sensed. In some embodiments, the sensor is placed near a bifurcation or an origin of an artery branch. The vibration or sound caused by blood flow will be correlated to the blood flow velocity or turbulence and/or blood pressure in the artery. Thus, by detecting and analyzing the characteristics of blood flow sound from an artery, a surrogate measure of blood flow velocity may be obtained. - Worsening myocardial contractility may be responded to at
block 420 by delivering a therapy and/or generating a patient or physician alert. A therapy delivered in response to worsening myocardial contractility may include cardiac pacing, neurostimulation, or drug delivery. Additional details regarding detecting worsening myocardial contractility are provided in conjunction withFIG. 8 . - Electrical-mechanical synchronization analysis is performed at
block 410 and may include analysis of acoustical signals from heart valves for determining synchrony between EGM events and valve-related sounds, synchrony between valves in left and right heart chambers and/or upper and lower heart chambers, changes in valve sounds signifying regurgitation, or appearance of an S3-related sound. If poor synchrony between the left and right sides of the patient's heart is detected as determined atblock 416, a therapy response or alert is provided atblock 420. In one embodiment, hydrophone signals are used for controlling cardiac resynchronization therapy (CRT) to improve cardiac chamber synchrony. Additional details relating to using hydrophone signals for detecting worsening synchrony and controlling CRT therapy are provided in conjunction withFIG. 7 . - The analyses performed at
blocks -
FIG. 6 is aflow chart 500 of one method for using hydrophone signals for controlling shock therapy. Atblock 502 an EGM signal is sensed from cardiac electrodes. Typically, the EGM signal (or an ECG signal) is a primary arrhythmia detection signal, monitored for initial detection of an arrhythmia. Initially, an arrhythmia is detected based on EGM signal monitoring, which may involve interval-based and/or morphology-based detection algorithms. When a preliminary arrhythmia detection is made based on EGM signal monitoring, hydrophones directed to receive signals specific to the mitral valve and the aortic valve are enabled atblock 504 for providing acoustical signals to the IMD processing circuitry. - At
block 504, hydrophone signals are received corresponding to the mitral valve and the aortic valve. The association between an event sensed on the EGM signal, such as an R-wave, and an event on the hydrophone signal is determined atblock 506. Detecting association would include a 1:1 correspondence of the EGM and hydrophone signal events and occurrence of the events within an expected time interval range. Accordingly, time intervals between an EGM signal event and a hydrophone signal event are measured atblock 506 to determine if there is electrical-to-mechanical correlation between these events atdecision block 510. If not, the rhythm is detected as a shockable rhythm and cardioversion/defibrillation shock therapy is delivered atblock 520. - If electrical and mechanical events are found to be correlated at
block 510, time intervals between atrial EGM signals and valve-related sounds are measured atblock 512. If there is correlation between atrial electrical activity, e.g. a P-wave, and valve sounds, the rhythm is determined to be a supraventricular rhythm and a cardioversion/defibrillation shock is withheld atblock 518. If atrial EGM events are not associated with the aortic and mitral valve sounds at regular intervals, a ventricular arrhythmia is detected. - At
block 514, the hydrophone signals are used to determine whether the ventricular arrhythmia is hemodynamically stable. The morphology of a hydrophone signal received from the direction of the aortic valve may be analyzed to determine if an expected signal morphology is present. The morphology analysis may include determining peak amplitudes and comparing the amplitude variability from beat-to-beat or comparing a peak amplitude to a threshold. Morphology analysis may include determining frequency content as sensed by multiple frequency range-specific transducers included in the hydrophone. If the frequency power spectrum changes significantly from an expected frequency power spectrum for normal sinus rhythm, hemodynamic instability may be detected. Baseline or threshold features of the hydrophone signals during normal sinus rhythm may be previously established and used for comparison atblock 514. - High frequency signal components may provide blood flow information relating to changes in flow velocity, flow turbulence, valve regurgitation or other flow changes that an accelerometer or other acoustical sensors are insensitive to. Analysis of acoustical signals correlated to blood flow is not limited to signals arising from flow through a cardiac valve but may also include signals received by a hydrophone directed toward the aorta or other large artery or within a ventricular chamber.
- Time intervals between the mitral valve signal events and the aortic valve signal events may also be examined at
block 514. If stable acoustical signal morphology is found with no new sounds present, the ventricular tachycardia is detected as being hemodynamically stable. Shock therapy is withheld atblock 518. - The process returns to block 501 and continues to acquire EGM and hydrophone signals until an arrhythmia is no longer detected or until the rhythm deteriorates to a hemodynamically unstable ventricular tachycardia as determined by the analyses performed at
blocks block 520. New sounds detected atblock 514 may include sounds corresponding to S3 or S4 heart sounds. -
FIG. 7 is aflow chart 600 of a method for monitoring a heart failure condition using implantable hydrophones. Hydrophones carried by transvenous leads are positioned at targeted sensing locations atblock 602 for directional sensing of specific arterial and cardiac sounds. Each hydrophone may include multiple transducers for sensitivity in individually specific frequency ranges. In one embodiment, one hydrophone is directed toward the mitral valve in the LV and another one toward the tricuspid valve in the RV. Additional hydrophones may be directed toward the aorta or pulmonary artery or another large artery, the aortic valve, the pulmonic valve, along the LV, along the RV or other desired monitoring locations. Methods described herein will relate to one hydrophone directed toward the mitral valve and one hydrophone directed to the tricuspid valve, however it is recognized that these methods may be expanded to include analysis of acoustical signals received by hydrophones directed to receive sounds from other cardiovascular locations. - At
block 604, the hydrophone signals are recorded on a periodic basis, e.g. hourly, daily, weekly, monthly or other interval selected by a clinician. Atblock 606 through 612, the signals are analyzed to detect evidence of worsening HF or ventricular dyssynchrony. - At
block 606, the amplitudes of the hydrophone signals are measured. Amplitude measurements may include determining a maximum or peak-to-peak amplitude from each transducer signal included in each hydrophone during a cardiac cycle or a portion thereof. As such, the sound intensity in multiple frequency ranges is measured for each hydrophone, i.e. for each directional sensing location. For example, the intensity of the mitral valve sounds in each of four frequency ranges and the intensity of the tricuspid valve sounds in each of four frequency ranges may be measured atblock 606 from two hydrophones directed to preferentially receive mitral valve and tricuspid valve sounds, respectively. The number of frequency ranges monitored will depend on the number of transducers included in each hydrophone. All or a subset of available frequencies may be used for initial detection of a change in ventricular synchrony or HF status. - At
block 608, time intervals between the left and right heart valve sounds are measured. For example, in a given frequency range, the time interval between a maximum signal peak in a mitral valve sound and a maximum signal peak in a tricuspid valve sound may be measured. - The appearance of any new acoustical signal components is determined at
block 610. Occurrence of new sounds during time intervals not previously sensed may be an indication of a pathological change. For example, the appearance of sounds occurring during ventricular diastole relating to the S3 and S4 heart sounds may indicate a deteriorating heart failure condition. Increased signal intensity during time intervals or in frequency ranges not associated with normal acoustical signal intensity may indicate valve regurgitation, dilation of the heart, ventricular dyssynchrony, changing blood pressure or flow patterns, or other conditions associated with worsening heart failure. The appearance of new acoustical signal components, i.e. increased intensity of the acoustical signal, may be measured by measuring amplitudes or signal power for each of multiple frequency ranges and/or multiple time windows during the cardiac cycle. - At
block 614, the measurements performed atblock - If worsening HF is detected, time intervals between a fiducial point of the EGM sensed QRS signal and an acoustical event associated with mitral and/or tricuspid valve closure are measured and compared to a predefined optimal time interval range or baseline at
block 616. The time interval may be measured between an onset or peak of the QRS complex and an onset or peak of an S1 sound, for example. If the QRS-mitral valve (MV) time interval is outside an optimal time interval range, e.g. a threshold change from a previously established baseline measurement, the AV interval used to control CRT is adjusted atblock 618. The AV interval may be adjusted until the QRS-MV time interval is within the optimal range, e.g. within a threshold range of the baseline measurement, or other optimization criteria may be used. An example of a threshold range that may be used is approximately ±20 ms. - After adjusting the AV interval or verifying that the QRS-MV interval is within a desired range, a time interval is measured between fiducial points of the acoustical signals received from the MV and from the tricuspid valve at
block 620. If the time interval is within a predefined range, e.g. within a threshold range such as within of a previously established baseline measurement, indicating synchrony of the left and right heart chambers as determined atblock 620, the process advances to block 624. Otherwise, the inter-ventricular (VV) timing interval used to control CRT pacing pulses is adjusted atblock 622. The VV interval may be adjusted until fiducial points, such as a peak amplitude, of the MV and tricuspid valve signals are synchronized in one embodiment though other optimization criteria may be used. If the fiducial points of the two valve signals are within approximately 20 ms, the ventricles may be considered synchronized in one example. - After optimizing the AV and VV intervals if needed in response to the measured QRS-MV interval and the MV-tricuspid valve interval, the acoustical signals are examined for evidence of HF decompensation at
block 624. After performing optimization of CRT, if evidence of HF decompensation remains, e.g., evidence of valve regurgitation, weakened (lower amplitude) or altered acoustical signal morphology, or presence of unexpected or abnormal acoustical signal components (in time or frequency domain), an alert may be generated atblock 626 to notify the patient or clinician that medical attention may be warranted. Additionally or alternatively, a new therapy may be administered, which may involve neuromodulation using electrical stimulation or pharmacologic agents, or other automatic delivery of heart failure medication. The alert may notify the patient to take prescribed medications. -
FIG. 8 is aflow chart 700 of one method for detecting acute myocardial infarction (AM I) according to one embodiment. Acoustical signals detected by hydrophones having specific orientations for directional sensing of cardiac sounds are used in conjunction with EGM (or ECG) signal monitoring for evidence of myocardial ischemia. Atblock 701, S-T segment monitoring of the EGM signal is performed. S-T segment deviation is an indication of myocardial ischemia. Detection of S-T segment changes atblock 702 may be performed as generally disclosed in U.S. Pat. No. 6,937,899 B2 (Sheldon, et al.), hereby incorporated herein by reference in its entirety. - If a deviation in the S-T segment is sustained for a predetermined period of time or number of cardiac cycles, as determined at
block 704, confirmation of AMI detection may be made atblock 714. In some cases, however, the EGM signal analysis alone may not be conclusive. The S-T segment change may not reach a threshold change for a sustained period of time or the signal-to-noise ratio may preclude ischemia detection based on the EGM signal alone. If an S-T segment change is detected but EGM signal analysis is inconclusive in detecting AMI, one or more hydrophone signals are obtained atblock 706. - In response to an S-T change that is either non-sustained or not reaching other threshold criteria, such as a threshold S-T elevation or depression, for detecting AMI, one or more hydrophone signals are monitored at
block 706. Hydrophone signals are monitored for evidence of weakened contractility of the myocardium which may include altered flow patterns, valve regurgitation and increased intensity of diastolic sounds S3 and S4. Valve regurgitation sounds sensed primarily from the mitral or tricuspid valves are an indication of weak ventricular contraction during ischemia which causes weakened valve closure or dyssynchronous closures. In one embodiment, a hydrophone directed toward the mitral valve or aortic valve is used for sensing changes in valve sounds such as the appearance valve regurgitation, or changes in the amplitude, morphology or frequency content of mitral valve or aortic valve closure sounds. Since S3/S4 occurs during relaxation of ventricles and may be caused by free ventricular free wall vibration, a hydrophone may be directed to the LV free wall for sensing S3- or S4-related sounds. - If an S-T segment change is transient without correlation to compromised contractility based on heart sounds, as determined at
block 708, the episode may be benign. The process may return to block 704 to continue to monitor for S-T segment deviation. If evidence of decreased contractility is detected from the hydrophone signals atblock 708, measured changes in the hydrophone signal(s) may be compared to AMI detection thresholds atblock 710. If intensity, frequency or morphology changes in the hydrophone signal(s) reach an AMI detection threshold, and/or changes in hydrophone signals are correlated in time with S-T segment changes, AMI is detected atblock 714. Otherwise, the changes are attributed to myocardial ischemia atblock 712. During AMI, either ST elevation or non-ST elevation AMI, the contractility will be compromised and this evidence can be obtained from the acoustical signals. During transient ischemia episodes, ischemia is typically short and not severe enough to compromise functionality. Thus transient or benign myocardial ischemia and AMI can be discriminated based on hydrophone signals. - Using one or more acoustic sensors, global versus local ischemia may be distinguishable as well as a general location of an infarct or ischemic area. For example, using multiple hydrophones having different directionality, the changes in acoustical signals may indicate the myocardial contraction is globally weak due to changes in multiple signals from multiple directions or only abnormal from a specific direction. EGM S-T segment deviation detected by an LV lead in conjunction with acoustical signal change associated with the mitral valve performance may indicate the ischemia/infarct location is in the LV free wall. EGM S-T segment deviation detected by an RV lead in conjunction with acoustical signal associated with tricuspid valve may indicate the ischemic/infarct location is in the RV. Identification of an area of suspected local ischemia may provide information regarding a location of coronary artery occlusion or stenosis and may be useful in guiding a therapy response and further diagnostic testing.
- At
block 716, an alert and/or therapy response is provided. If AMI is detected atblock 714, an alert may be generated to notify the patient and clinician that immediate medical attention is warranted. A therapy may be adjusted, terminated or initiated in response to AMI detection. A therapy delivered in response to AMI detection may be a change to medication delivered by a drug pump, neuromodulation such as spinal cord stimulation for reducing sympathetic excitation, or a pacing therapy to reduce the heart rate. If myocardial ischemia is detected atblock 712, a patient and/or clinician alert may be generated atblock 716 and an automated therapy may be delivered. Automatic therapies delivered in response to myocardial ischemia may include those listed above for responding to AMI. In the case of transient myocardial ischemia, no therapy may be indicated. In some cases, a therapy response may include termination of a therapy. For example, if a pacing therapy has been delivered, it may be terminated until medical attention is provided or ischemia is no longer detected. -
FIG. 9 is aflow chart 800 of a method for monitoring for hypertension using hydrophone signals. Atblock 801, one hydrophone is directionally positioned for receiving arterial sounds from an artery such as the pulmonary artery, aorta, or carotid artery. Typically the hydrophone will be placed transvenously with the hydrophone directed toward an artery for receiving a sound signal from an adjacent artery. For example, a hydrophone may be positioned in the left innominate vein and directed to receive acoustical signals from the aorta. A second hydrophone may be directionally positioned for receiving signals from a cardiac valve such as the aortic valve or the pulmonic valve. - At
block 802, a signal from the hydrophone directed to the aortic or pulmonic valve is monitored. A particular narrow band frequency may be selected for sensing from one of multiple transducers included in the hydrophone to obtain a signal associated with the closure of the valve with high specificity and sensitivity. If an increase in intensity of the sound associated with valve closure is detected atblock 804, e.g. compared to a baseline or predetermined threshold value, the arterial sound is monitored atblock 806. In particular the arterial signal may be monitored during aortic or pulmonic valve closure. If the intensity of the arterial sound signal increases during valve closure, an increase in blood pressure is detected atblock 808. Other aspects of the arterial signal may be monitored for detecting increased blood pressure, such as examining particular frequency components for evidence of increased blood flow velocity. Hydrophone signal frequency components may be correlated to blood flow velocity through calibration techniques at the time of manufacture. For example using a blood flow loop, hydrophone signal frequency content may be calibrated for varying flow velocities and pressures. - If an increase in blood pressure is detected, a patient or clinician alert and/or a therapy response may be provided at
block 810. A therapy response to increased blood pressure may include neurostimulation to cause vasodilation or delivery of a vasodilator drug. - Thus, a medical device system and associated methods for acquiring and monitoring acoustical signals related to cardiac function have been presented in the foregoing description with reference to specific embodiments. It is understood that the various techniques and devices described may be implemented in any combination. It is appreciated that various modifications to the referenced embodiments may be made without departing from the scope of the disclosure as set forth in the following claims.
Claims (22)
1. An implantable medical lead, comprising:
an elongated lead body having an outer surface and an opening along the outer surface; and
a sensor positioned along the lead body and configured to receive acoustic signals through the opening of the lead body and generate an electrical signal representative of sounds produced at a targeted location along a patient's cardiovascular system, wherein the outer surface comprises a shaped contour for directing the opening for receiving the acoustic signals from a direction of the targeted location.
2. The lead of claim 1 , wherein the sensor comprises a hydrophone, the hydrophone comprising a plurality of transducers each responsive to a distinct sound frequency range and generating an electrical signal representative of sounds produced at the targeted location in the respective distinct sound frequency range.
3. The lead of claim 1 , wherein the shaped contour comprises pre-shaped curve along the lead body.
4. The system of claim 3 wherein the sensor is positioned along the pre-shaped curve.
5. The lead of claim 3 , wherein the elongated body comprises a proximal end and a distal end, and wherein the sensor comprises a hydrophone being positioned distal to the pre-shaped curve.
6. The lead of claim 1 , wherein the shaped contour comprises a recessed surface surrounded by a sidewall.
7. The lead of claim 6 , further comprising a protruding flange extending along an edge of the side wall.
8. The lead of claim 1 , wherein the shaped contour comprises one of a convex surface and a concave surface.
9. The lead of claim 1 , wherein the elongated body comprises:
a proximal end, a distal end, an outer side extending between the proximal end and the distal end, and a J-shaped bend near the distal end,
a first opening distal to the J-shaped bend of the elongated body;
a second opening along the outer side proximal to the J-shaped bend; and
at least one recessed surface along the outer surface of the lead body and one of the first opening and the second opening extending along the recessed surface, and wherein the sensor comprises a hydrophone positioned along the first opening and a second hydrophone positioned along the second opening.
10. The lead of claim 1 , wherein the hydrophone comprises a piezoelectric transducer having an associated piezoelectric axis, the axis aligned in a direction corresponding to an origination direction corresponding to the targeted location when the lead body is implanted in the patient's body.
11. An implantable medical device system, comprising:
an elongated lead body having an outer surface and an opening along the outer surface;
a sensor positioned along the lead body and configured to receive acoustical signals through the opening of the lead body and generate an electrical signal representative of sounds produced at a targeted location along a patient's cardiovascular system;
the outer surface comprising a shaped contour for directing the opening for receiving the sounds from a direction of the targeted location; and
a processor receiving the sensor signal and detecting a cardiac condition in response to the signal.
12. The system of claim 11 , wherein the sensor comprises a hydrophone, the hydrophone comprising a plurality of transducers each responsive to a distinct sound frequency range and generating an electrical signal representative of sounds produced at the targeted location in the respective distinct sound frequency range.
13. The system of claim 12 , wherein the processor is configured to select a signal corresponding to a distinct sound frequency range from the plurality of transducers to be used for detecting the cardiac condition.
14. The system of claim 11 , wherein the shaped contour comprises pre-shaped curve along the lead body.
15. The system of claim 14 , wherein the sensor comprises a hydrophone, the hydrophone being positioned along the pre-shaped curve.
16. The system of claim 14 , wherein the elongated body comprises a proximal end and a distal end, and wherein the sensor comprises a hydrophone positioned distal to the pre-shaped curve.
17. The system of claim 11 , wherein the shaped contour comprises a recessed surface surrounded by a sidewall.
18. The system of claim 17 , further comprising a protruding flange extending along an edge of the side wall.
19. The system of claim 11 , wherein the shaped contour comprises one of a convex surface and a concave surface.
20. The system of claim 11 , wherein the elongated body comprises:
a proximal end, a distal end, an outer side extending between the proximal end and the distal end, and a J-shaped bend near the distal end, a first opening distal to the J-shaped bend of the elongated body;
a second opening along the outer side proximal to the J-shaped bend;
at least one recessed surface along the outer surface of the lead body and one of the first opening and the second opening extending along the recessed surface, and wherein the sensor comprises a first hydrophone positioned along the first opening and a second hydrophone positioned along the second opening.
21. The system of claim 11 , wherein the sensor comprises a hydrophone comprising a piezoelectric transducer having an associated piezoelectric axis, the axis aligned in a direction corresponding to an origination direction corresponding to the targeted location when the lead body is implanted in a patient's body.
22. A method for detecting a cardiac condition, comprising:
advancing an elongated lead body to a targeted location along a patient's cardiovascular system, the elongated lead body having an outer surface, an opening along the outer surface and carrying a hydrophone configured to receive acoustical signals through the opening and generate an electrical signal representative of sounds produced at the targeted location, the outer surface comprising a shaped contour for directing the opening for receiving the sounds from a direction of the targeted location; and
receiving the hydrophone signal and detect a cardiac condition in response to the signal.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/794,869 US20130289377A1 (en) | 2012-04-27 | 2013-03-12 | Method and apparatus for cardiac function monitoring |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261639234P | 2012-04-27 | 2012-04-27 | |
US13/794,869 US20130289377A1 (en) | 2012-04-27 | 2013-03-12 | Method and apparatus for cardiac function monitoring |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130289377A1 true US20130289377A1 (en) | 2013-10-31 |
Family
ID=49477866
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/794,869 Abandoned US20130289377A1 (en) | 2012-04-27 | 2013-03-12 | Method and apparatus for cardiac function monitoring |
US13/794,973 Active 2035-09-10 US9675315B2 (en) | 2012-04-27 | 2013-03-12 | Method and apparatus for cardiac function monitoring |
US13/794,898 Active US8926523B2 (en) | 2012-04-27 | 2013-03-12 | Method and apparatus for cardiac function monitoring |
US13/794,918 Abandoned US20130289378A1 (en) | 2012-04-27 | 2013-03-12 | Method and apparatus for cardiac function monitoring |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/794,973 Active 2035-09-10 US9675315B2 (en) | 2012-04-27 | 2013-03-12 | Method and apparatus for cardiac function monitoring |
US13/794,898 Active US8926523B2 (en) | 2012-04-27 | 2013-03-12 | Method and apparatus for cardiac function monitoring |
US13/794,918 Abandoned US20130289378A1 (en) | 2012-04-27 | 2013-03-12 | Method and apparatus for cardiac function monitoring |
Country Status (1)
Country | Link |
---|---|
US (4) | US20130289377A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130289379A1 (en) * | 2012-04-27 | 2013-10-31 | Medtronic, Inc. | Method and apparatus for cardiac function monitoring |
EP3669936A1 (en) * | 2018-12-20 | 2020-06-24 | Sorin CRM SAS | Implantable medical device for defibrillation of the heart based on the detection of mechanical vibrations |
CN111818966A (en) * | 2018-03-06 | 2020-10-23 | 美敦力公司 | Impulse detection for implantable medical devices |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112220593A (en) | 2015-02-12 | 2021-01-15 | 方德里创新研究第一有限公司 | Implantable devices for heart failure monitoring and related methods |
EP3331426B1 (en) | 2015-08-03 | 2024-07-24 | Foundry Innovation&Research 1, Ltd. | Catheter for measurement of vena cava dimension |
US10463295B2 (en) * | 2016-06-13 | 2019-11-05 | Medtronic, Inc. | Multi-parameter prediction of acute cardiac episodes and attacks |
US20180008206A1 (en) * | 2016-07-07 | 2018-01-11 | Cardiac Pacemakers, Inc. | Systems and methods to determine surrogates of blood pressure |
US11206992B2 (en) | 2016-08-11 | 2021-12-28 | Foundry Innovation & Research 1, Ltd. | Wireless resonant circuit and variable inductance vascular monitoring implants and anchoring structures therefore |
US11701018B2 (en) | 2016-08-11 | 2023-07-18 | Foundry Innovation & Research 1, Ltd. | Wireless resonant circuit and variable inductance vascular monitoring implants and anchoring structures therefore |
EP3496606A1 (en) | 2016-08-11 | 2019-06-19 | Foundry Innovation & Research 1, Ltd. | Systems and methods for patient fluid management |
CN109982738B (en) * | 2016-11-21 | 2021-06-22 | 心脏起搏器股份公司 | Delivery device and wall attachment sensing |
CA3043228A1 (en) | 2016-11-29 | 2018-06-07 | Foundry Innovation & Research 1, Ltd. | Wireless resonant circuit and variable inductance vascular implants for monitoring patient vasculature and fluid status and systems and methods employing same |
US20180196919A1 (en) * | 2017-01-10 | 2018-07-12 | International Business Machines Corporation | Automated health dialoguing and action enhancement |
US11779238B2 (en) | 2017-05-31 | 2023-10-10 | Foundry Innovation & Research 1, Ltd. | Implantable sensors for vascular monitoring |
US11944495B2 (en) | 2017-05-31 | 2024-04-02 | Foundry Innovation & Research 1, Ltd. | Implantable ultrasonic vascular sensor |
CN111031903B (en) | 2017-06-16 | 2023-08-04 | 康奈尔大学 | Method and system for electromagnetic near-field coherent sensing |
US11045163B2 (en) * | 2017-09-19 | 2021-06-29 | Ausculsciences, Inc. | Method of detecting noise in auscultatory sound signals of a coronary-artery-disease detection system |
WO2019191602A1 (en) * | 2018-03-29 | 2019-10-03 | Medtronic, Inc. | Left ventricular assist device adjustment and evaluation |
CN112714912B (en) | 2018-05-14 | 2024-07-09 | 康奈尔大学 | Cooperative RFID reader using Code Division Multiple Access (CDMA) and method therefor |
US20220175254A1 (en) * | 2019-03-26 | 2022-06-09 | Cornell University | Near-field coherent sensing methods and systems |
US20210007684A1 (en) * | 2019-07-09 | 2021-01-14 | Mistretta Medical, Llc | System and method of low dose ct fluoroscopy via aperture control |
DE102020204879B4 (en) * | 2020-04-17 | 2022-01-27 | Neven Dolos | Zipper, slider for a zipper and method of operating a zipper |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4805157A (en) * | 1983-12-02 | 1989-02-14 | Raytheon Company | Multi-layered polymer hydrophone array |
US5554177A (en) * | 1995-03-27 | 1996-09-10 | Medtronic, Inc. | Method and apparatus to optimize pacing based on intensity of acoustic signal |
US6115624A (en) * | 1997-07-30 | 2000-09-05 | Genesis Technologies, Inc. | Multiparameter fetal monitoring device |
US20040138572A1 (en) * | 2001-05-28 | 2004-07-15 | Arvind Thiagarajan | Heart diagnosis system |
US20060129061A1 (en) * | 2004-12-15 | 2006-06-15 | Masayuki Kaneto | Catheter and production method thereof |
US20070016068A1 (en) * | 2005-05-06 | 2007-01-18 | Sorin Grunwald | Ultrasound methods of positioning guided vascular access devices in the venous system |
US20070142866A1 (en) * | 2005-12-20 | 2007-06-21 | Cardiac Pacemakers, Inc. | Method and apparatus for controlling anti-tachyarrhythmia pacing using hemodynamic sensor |
US20070162080A1 (en) * | 2004-06-10 | 2007-07-12 | Cardiac Pacemakers, Inc. | Method and apparatus for optimization of cardiac resynchronization therapy using heart sounds |
US20070208390A1 (en) * | 2006-03-01 | 2007-09-06 | Von Arx Jeffrey A | Implantable wireless sound sensor |
US7274965B1 (en) * | 2005-02-07 | 2007-09-25 | Pacesetter, Inc. | Trans-septal intra-cardiac lead system |
US20080154144A1 (en) * | 2006-08-08 | 2008-06-26 | Kamil Unver | Systems and methods for cardiac contractility analysis |
US7559900B2 (en) * | 2005-04-22 | 2009-07-14 | Medtronic, Inc. | Cardiac sensing and detection using subcutaneous ECG signals and heart sounds |
US20100331903A1 (en) * | 2009-06-30 | 2010-12-30 | Medtronic, Inc. | Heart sound sensing to reduce inappropriate tachyarrhythmia therapy |
US20120296228A1 (en) * | 2011-05-19 | 2012-11-22 | Medtronic, Inc. | Heart sounds-based pacing optimization |
US8494631B2 (en) * | 2011-08-31 | 2013-07-23 | Medtronic, Inc. | System and method for profiling a patients hemodynamic response based on heart sounds |
US20130289378A1 (en) * | 2012-04-27 | 2013-10-31 | Medtronic, Inc. | Method and apparatus for cardiac function monitoring |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4681117A (en) | 1983-02-15 | 1987-07-21 | Brodman Richard F | Intracardiac catheter and a method for detecting myocardial ischemia |
US4672976A (en) | 1986-06-10 | 1987-06-16 | Cherne Industries, Inc. | Heart sound sensor |
US5168869A (en) | 1991-06-17 | 1992-12-08 | Raul Chirife | Rate responsive pacemaker controlled by isovolumic contraction time |
EP1658808A1 (en) * | 1994-09-02 | 2006-05-24 | Volcano Corporation | Microminiature pressure sensor and guidewire using the same |
US6442433B1 (en) | 1999-10-26 | 2002-08-27 | Medtronic, Inc. | Apparatus and method for remote troubleshooting, maintenance and upgrade of implantable device systems |
US7738936B1 (en) * | 1999-11-10 | 2010-06-15 | Pacesetter, Inc. | Methods and systems for reducing data acquisition, power and/or processing for pulse oximetry applications |
US6418346B1 (en) | 1999-12-14 | 2002-07-09 | Medtronic, Inc. | Apparatus and method for remote therapy and diagnosis in medical devices via interface systems |
US6480745B2 (en) | 1999-12-24 | 2002-11-12 | Medtronic, Inc. | Information network interrogation of an implanted device |
US6650940B1 (en) | 2000-02-02 | 2003-11-18 | Cardiac Pacemakers, Inc. | Accelerometer-based heart sound detection for autocapture |
EP1265525A2 (en) | 2000-03-17 | 2002-12-18 | Medtronic Inc. | Heart failure monitor quick look summary for patient management systems |
US7052466B2 (en) | 2001-04-11 | 2006-05-30 | Cardiac Pacemakers, Inc. | Apparatus and method for outputting heart sounds |
US6937899B2 (en) | 2001-08-30 | 2005-08-30 | Medtronic, Inc. | Ischemia detection |
EP1536852B1 (en) | 2002-09-10 | 2016-11-16 | MED-EL Elektromedizinische Geräte GmbH | Implantable medical device with multiple transducers |
US8303511B2 (en) | 2002-09-26 | 2012-11-06 | Pacesetter, Inc. | Implantable pressure transducer system optimized for reduced thrombosis effect |
US7972275B2 (en) * | 2002-12-30 | 2011-07-05 | Cardiac Pacemakers, Inc. | Method and apparatus for monitoring of diastolic hemodynamics |
WO2004067081A2 (en) | 2003-01-24 | 2004-08-12 | Proteus Biomedical Inc. | Methods and apparatus for enhancing cardiac pacing |
EP1585441A4 (en) * | 2003-01-24 | 2008-05-21 | Proteus Biomedical Inc | Methods and systems for measuring cardiac parameters |
US6869404B2 (en) | 2003-02-26 | 2005-03-22 | Medtronic, Inc. | Apparatus and method for chronically monitoring heart sounds for deriving estimated blood pressure |
US6885889B2 (en) | 2003-02-28 | 2005-04-26 | Medtronic, Inc. | Method and apparatus for optimizing cardiac resynchronization therapy based on left ventricular acceleration |
US7218966B2 (en) * | 2003-04-11 | 2007-05-15 | Cardiac Pacemakers, Inc. | Multi-parameter arrhythmia discrimination |
US7668594B2 (en) * | 2005-08-19 | 2010-02-23 | Cardiac Pacemakers, Inc. | Method and apparatus for delivering chronic and post-ischemia cardiac therapies |
US7431699B2 (en) * | 2003-12-24 | 2008-10-07 | Cardiac Pacemakers, Inc. | Method and apparatus for third heart sound detection |
US7203541B2 (en) | 2004-03-12 | 2007-04-10 | Medtronic, Inc. | Real-time optimization of right to left ventricular timing sequence in bi-ventricular pacing of heart failure patients |
US7522962B1 (en) * | 2004-12-03 | 2009-04-21 | Remon Medical Technologies, Ltd | Implantable medical device with integrated acoustic transducer |
US20060178586A1 (en) * | 2005-02-07 | 2006-08-10 | Dobak John D Iii | Devices and methods for accelerometer-based characterization of cardiac function and identification of LV target pacing zones |
US7424321B2 (en) | 2005-05-24 | 2008-09-09 | Cardiac Pacemakers, Inc. | Systems and methods for multi-axis cardiac vibration measurements |
US7922669B2 (en) * | 2005-06-08 | 2011-04-12 | Cardiac Pacemakers, Inc. | Ischemia detection using a heart sound sensor |
US7998091B2 (en) | 2005-11-23 | 2011-08-16 | 3M Innovative Properties Company | Weighted bioacoustic sensor and method of using same |
US7580746B2 (en) * | 2005-12-07 | 2009-08-25 | Cardiac Pacemakers, Inc. | Implantable medical device for generating cardiac pressure-volume loop and optimizing therapy |
US8005543B2 (en) * | 2006-05-08 | 2011-08-23 | Cardiac Pacemakers, Inc. | Heart failure management system |
US20080039733A1 (en) | 2006-08-08 | 2008-02-14 | Kamil Unver | Systems and methods for calibration of heart sounds |
US7914452B2 (en) | 2006-10-10 | 2011-03-29 | Cardiac Pacemakers, Inc. | Method and apparatus for controlling cardiac therapy using ultrasound transducer |
US8442639B2 (en) * | 2007-02-13 | 2013-05-14 | Cardiac Pacemakers, Inc. | Systems and methods for electrical stimulation of blood vessels |
US8298153B2 (en) | 2008-07-09 | 2012-10-30 | Medtronic, Inc. | System and method for the detection of acute myocardial infarction |
EP2453975B1 (en) | 2009-07-15 | 2016-11-02 | Cardiac Pacemakers, Inc. | Remote sensing in an implantable medical device |
US8409108B2 (en) | 2009-11-05 | 2013-04-02 | Inovise Medical, Inc. | Multi-axial heart sounds and murmur detection for hemodynamic-condition assessment |
JP5526421B2 (en) * | 2010-10-12 | 2014-06-18 | 学校法人福岡大学 | Physical information measuring device and physical information measuring method |
-
2013
- 2013-03-12 US US13/794,869 patent/US20130289377A1/en not_active Abandoned
- 2013-03-12 US US13/794,973 patent/US9675315B2/en active Active
- 2013-03-12 US US13/794,898 patent/US8926523B2/en active Active
- 2013-03-12 US US13/794,918 patent/US20130289378A1/en not_active Abandoned
Patent Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4805157A (en) * | 1983-12-02 | 1989-02-14 | Raytheon Company | Multi-layered polymer hydrophone array |
US5554177A (en) * | 1995-03-27 | 1996-09-10 | Medtronic, Inc. | Method and apparatus to optimize pacing based on intensity of acoustic signal |
US6115624A (en) * | 1997-07-30 | 2000-09-05 | Genesis Technologies, Inc. | Multiparameter fetal monitoring device |
US20040138572A1 (en) * | 2001-05-28 | 2004-07-15 | Arvind Thiagarajan | Heart diagnosis system |
US7953484B2 (en) * | 2004-06-10 | 2011-05-31 | Cardiac Pacemakers, Inc. | Method and apparatus for optimization of cardiac resynchronization therapy using heart sounds |
US20070162080A1 (en) * | 2004-06-10 | 2007-07-12 | Cardiac Pacemakers, Inc. | Method and apparatus for optimization of cardiac resynchronization therapy using heart sounds |
US20060129061A1 (en) * | 2004-12-15 | 2006-06-15 | Masayuki Kaneto | Catheter and production method thereof |
US7632236B2 (en) * | 2004-12-15 | 2009-12-15 | Nitto Denko Corporation | Catheter and production method thereof |
US7274965B1 (en) * | 2005-02-07 | 2007-09-25 | Pacesetter, Inc. | Trans-septal intra-cardiac lead system |
US7559900B2 (en) * | 2005-04-22 | 2009-07-14 | Medtronic, Inc. | Cardiac sensing and detection using subcutaneous ECG signals and heart sounds |
US20070016068A1 (en) * | 2005-05-06 | 2007-01-18 | Sorin Grunwald | Ultrasound methods of positioning guided vascular access devices in the venous system |
US8409103B2 (en) * | 2005-05-06 | 2013-04-02 | Vasonova, Inc. | Ultrasound methods of positioning guided vascular access devices in the venous system |
US20070142866A1 (en) * | 2005-12-20 | 2007-06-21 | Cardiac Pacemakers, Inc. | Method and apparatus for controlling anti-tachyarrhythmia pacing using hemodynamic sensor |
US20070208390A1 (en) * | 2006-03-01 | 2007-09-06 | Von Arx Jeffrey A | Implantable wireless sound sensor |
US20080154144A1 (en) * | 2006-08-08 | 2008-06-26 | Kamil Unver | Systems and methods for cardiac contractility analysis |
US20100331903A1 (en) * | 2009-06-30 | 2010-12-30 | Medtronic, Inc. | Heart sound sensing to reduce inappropriate tachyarrhythmia therapy |
US20120296228A1 (en) * | 2011-05-19 | 2012-11-22 | Medtronic, Inc. | Heart sounds-based pacing optimization |
US8494631B2 (en) * | 2011-08-31 | 2013-07-23 | Medtronic, Inc. | System and method for profiling a patients hemodynamic response based on heart sounds |
US20130289378A1 (en) * | 2012-04-27 | 2013-10-31 | Medtronic, Inc. | Method and apparatus for cardiac function monitoring |
US8926523B2 (en) * | 2012-04-27 | 2015-01-06 | Medtronic, Inc. | Method and apparatus for cardiac function monitoring |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130289379A1 (en) * | 2012-04-27 | 2013-10-31 | Medtronic, Inc. | Method and apparatus for cardiac function monitoring |
US9675315B2 (en) * | 2012-04-27 | 2017-06-13 | Medtronic, Inc. | Method and apparatus for cardiac function monitoring |
CN111818966A (en) * | 2018-03-06 | 2020-10-23 | 美敦力公司 | Impulse detection for implantable medical devices |
EP3669936A1 (en) * | 2018-12-20 | 2020-06-24 | Sorin CRM SAS | Implantable medical device for defibrillation of the heart based on the detection of mechanical vibrations |
US20200197714A1 (en) * | 2018-12-20 | 2020-06-25 | Sorin Crm Sas | Implantable medical device for defibrillation of the heart based on the detection of mechanical vibrations |
JP2020121107A (en) * | 2018-12-20 | 2020-08-13 | ソーリン シーアールエム エス ア エスSorin Crm S.A.S. | Implantable medical device for defibrillation of heart based on detection of mechanical vibrations |
JP2023022120A (en) * | 2018-12-20 | 2023-02-14 | ソーリン シーアールエム エス ア エス | Implant type medical device for heart defibrillation by detecting mechanical vibrations |
US11666770B2 (en) * | 2018-12-20 | 2023-06-06 | Sorin Crm Sas | Implantable medical device for defibrillation of the heart based on the detection of mechanical vibrations |
Also Published As
Publication number | Publication date |
---|---|
US8926523B2 (en) | 2015-01-06 |
US9675315B2 (en) | 2017-06-13 |
US20130289430A1 (en) | 2013-10-31 |
US20130289378A1 (en) | 2013-10-31 |
US20130289379A1 (en) | 2013-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9675315B2 (en) | Method and apparatus for cardiac function monitoring | |
US11305124B2 (en) | System and method for pacing parameter optimization using heart sounds | |
US11850063B2 (en) | Multi-parameter prediction of acute cardiac episodes and attacks | |
US11844949B2 (en) | Cardiac defibrillation | |
JP5203183B2 (en) | Device for assessing ventricular function during isovolumetric contraction | |
US7668594B2 (en) | Method and apparatus for delivering chronic and post-ischemia cardiac therapies | |
US9265949B2 (en) | Method and apparatus for controlling cardiac therapy based on electromechanical timing | |
US20170224995A1 (en) | Cardiac pacing sensing and control | |
US8403860B2 (en) | Method and apparatus for detecting atrial filling pressure | |
EP1423163B1 (en) | System for detecting myocardial ischemia | |
US8494631B2 (en) | System and method for profiling a patients hemodynamic response based on heart sounds | |
JP5178815B2 (en) | Closed-loop resynchronization treatment of dyssynchrony | |
JP2008534218A (en) | A neural stimulator synchronized to the cardiac cycle | |
CN111417433A (en) | Method and system for detecting atrial contraction timing reference during ventricular filling from a ventricular implanted leadless cardiac pacemaker | |
US20230329584A1 (en) | Body stability measurement | |
WO2022194817A1 (en) | Indirect sensing mechanism for cardiac monitoring | |
CN111432874A (en) | Method and system for detecting atrial contraction timing reference within search window from a ventricular implanted leadless cardiac pacemaker | |
US11931586B2 (en) | Cardiac pacing sensing and control | |
US20230016125A1 (en) | Cardiac defibrillation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MEDTRONIC, INC., MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SONG, ZHENDONG;ZHOU, XIAOHONG;REEL/FRAME:030408/0983 Effective date: 20130513 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |